PRODUCT MONOGRAPH

Pr ABILIFY MAINTENA®
Aripiprazole for prolonged release injectable suspension

300 mg and 400 mg vial
300 mg and 400 mg dual chamber syringe

Antipsychotic agent

Otsuka Pharmaceutical Co., Ltd.
Tokyo, 101-8535 Japan

Date of Revision:
November 1, 2017

Imported by:
Otsuka Canada Pharmaceutical Inc.
Saint-Laurent, QC
H4S 2C9

Control # 200292

Marketed by:
Otsuka Canada Pharmaceutical Inc.
Saint-Laurent, QC
H4S 2C9

Lundbeck Canada Inc.
Saint-Laurent, QC
H4S 0A9

Otsuka Canada Pharmaceutical Inc.
Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3
  SUMMARY PRODUCT INFORMATION ................................................................. 3
  INDICATIONS AND CLINICAL USE ................................................................. 3
  CONTRAINDICATIONS ..................................................................................... 4
  WARNINGS AND PRECAUTIONS ..................................................................... 4
  ADVERSE REACTIONS ...................................................................................... 11
  DRUG INTERACTIONS ....................................................................................... 24
  DOSAGE AND ADMINISTRATION .................................................................. 25
  OVERDOSAGE .................................................................................................. 35
  ACTION AND CLINICAL PHARMACOLOGY .................................................. 36
  STORAGE AND STABILITY .............................................................................. 39
  DOSAGE FORMS, COMPOSITION AND PACKAGING ..................................... 39

PART II: SCIENTIFIC INFORMATION ................................................................. 40
  PHARMACEUTICAL INFORMATION ................................................................. 40
  CLINICAL TRIALS ............................................................................................ 40
  DETAILED PHARMACOLOGY ......................................................................... 47
  TOXICOLOGY .................................................................................................... 49
  REFERENCES .................................................................................................... 53

PART III: CONSUMER INFORMATION ............................................................... 55
Pr ABILIFY MAINTENA®

Aripiprazole for prolonged release injectable suspension

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength</th>
<th>Non-medicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intra-muscular injection</td>
<td>300 mg vial</td>
<td>carboxymethyl cellulose sodium mannitol</td>
</tr>
<tr>
<td></td>
<td>400 mg vial</td>
<td>sodium phosphate monobasic monohydrate</td>
</tr>
<tr>
<td></td>
<td>300 mg dual chamber syringe</td>
<td>sodium hydroxide</td>
</tr>
<tr>
<td></td>
<td>400 mg dual chamber syringe</td>
<td></td>
</tr>
</tbody>
</table>

INDICATIONS AND CLINICAL USE

Schizophrenia
ABILIFY MAINTENA (aripiprazole for prolonged release injectable suspension) is indicated for the treatment of schizophrenia in adult patients. Efficacy has been established in both acute and maintenance phases of schizophrenia.

In a controlled clinical trial in subjects in the acute phase of schizophrenia, ABILIFY MAINTENA was superior to placebo in improving both positive and negative symptoms of schizophrenia.

In controlled clinical trials, ABILIFY MAINTENA was found to prevent relapse for up to 38 weeks after stabilization with oral aripiprazole.

Bipolar Disorder
ABILIFY MAINTENA (aripiprazole for prolonged release injectable suspension) is indicated for the maintenance monotherapy treatment of bipolar I disorder in adult patients.

In a controlled clinical trial in adult patients with bipolar I disorder, ABILIFY MAINTENA significantly reduced the risk of recurrence of any mood episode over 52 weeks compared with placebo.

Geriatrics (> 65 years of age):
ABILIFY MAINTENA is not indicated in elderly patients with dementia (see WARNINGS AND PRECAUTIONS – Serious Warnings and Precaution Box and Special Populations). The safety and efficacy of ABILIFY MAINTENA in patients 65 years of age or older have not been established. Caution should be used when treating geriatric patients (see WARNINGS AND PRECAUTIONS, Special Populations and ACTION AND CLINICAL PHARMACOLOGY).
Pediatrics (< 18 years of age): Safety and efficacy of ABILIFY MAINTENA have not been established in patients under 18 years of age and its use is not recommended.

CONTRAINDICATIONS

ABILIFY MAINTENA (aripiprazole for prolonged release injectable suspension) is contraindicated in those patients with a known hypersensitivity to aripiprazole or the excipients of the product. For a complete listing, see DOSAGE FORMS, COMPOSITION AND PACKAGING.

WARNINGS AND PRECAUTIONS

<table>
<thead>
<tr>
<th>Serious Warnings and Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased Mortality in Elderly Patients with Dementia</td>
</tr>
<tr>
<td>Elderly patients with dementia treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Analyses of thirteen placebo-controlled trials with various atypical antipsychotics (modal duration of 10 weeks) in these patients showed a mean 1.6-fold increase in the death rate in the drug-treated patients. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature (see WARNINGS AND PRECAUTIONS - Special Populations, Use in Elderly Patients with Dementia). ABILIFY MAINTENA is not approved for the treatment of patients with dementia.</td>
</tr>
</tbody>
</table>

General

Body Temperature Regulation
Disruption of the body’s ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing ABILIFY MAINTENA for patients who will be experiencing conditions which may contribute to an elevation in core body temperature (e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration).

Carcinogenesis and Mutagenesis
For animal data, see Part II: TOXICOLOGY section.

Cardiovascular

Orthostatic Hypotension
Aripiprazole may be associated with orthostatic hypotension, perhaps due to its α1-adrenergic receptor antagonism. Aripiprazole may induce orthostatic hypotension, tachycardia, dizziness, and sometimes syncope, especially at the initiation of treatment.
In the placebo-controlled trial in acute schizophrenia, presyncope occurred in 1/167 (0.6%) of patients treated with ABILIFY MAINTENA, while syncope and orthostatic hypotension each occurred in 1/172, (0.6%) of patients treated with placebo. There were no significant orthostatic changes in blood pressure for the ABILIFY MAINTENA-treated patients or placebo-treated patients (defined as a decrease in systolic blood pressure ≥20 mmHg accompanied by an increase in heart rate ≥25 when comparing standing to supine values).

In the double-blind controlled phase of the schizophrenia maintenance clinical trials using ABILIFY MAINTENA, orthostatic related events were reported in 2/534 (0.4%) patients. Orthostasis occurred in 4/576 (0.7%) patients treated with ABILIFY MAINTENA during the stabilization phase, including abnormal orthostatic blood pressure (1/576, 0.2%), postural dizziness (1/576, 0.2%), presyncope (1/576, 0.2%) and orthostatic hypotension (1/576, 0.2%). In the stabilization phase, the incidence of significant orthostatic change in blood pressure was 0.2% (1/575).

During the stabilization phase of the maintenance trial in adult patients with bipolar I disorder, syncope was the only orthostatic related adverse event reported in 0.2% of patients treated with ABILIFY MAINTENA. Incidence of potential clinically relevant orthostatic hypotension reported during the ABILIFY MAINTENA stabilization phase in bipolar I disorder was 0.2% (1/421) and during the double-blind, placebo-controlled phase, there were no differences reported in either treatment group.

The incidence of orthostatic hypotension-associated events from short-term, placebo-controlled trials of adult patients on oral aripiprazole (n=2643) included (aripiprazole incidence, placebo incidence): orthostatic hypotension (1.0%, 0.3%), postural dizziness (0.5%, 0.3%), and syncope (0.5%, 0.3%).

Aripiprazole should be used with caution in patients with known cardiovascular disease (e.g. history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). Patients with a history of clinically significant cardiovascular disorders were excluded from clinical trials.

**QT Interval**

In clinical trials with ABILIFY MAINTENA, the incidence of QT prolongation was comparable to placebo. In post-marketing experience, QT prolongation has been reported very rarely with aripiprazole treatment. As with other antipsychotics, aripiprazole should be used with caution in patients with conditions such as congenital long QT syndrome and acquired long QT syndrome (e.g., due to concomitant use of a drug that prolongs the QT); a family history of QT prolongation; or other clinical conditions that predispose to arrhythmias (e.g., hypokalemia or hypomagnesemia or hypocalcemia).

**Endocrine and Metabolism**

**Hyperglycemia and Diabetes Mellitus**

Diabetic ketoacidosis has occurred in patients treated with antipsychotics with no reported history of hyperglycemia. As with some other antipsychotics, exacerbation of pre-existing diabetes and hyperglycemia have been reported rarely and diabetic ketoacidosis and diabetic coma including some fatal cases, have been reported very rarely during the use of oral aripiprazole. In schizophrenia clinical trials with ABILIFY MAINTENA there have been few reports of hyperglycemia and diabetes, the incidence was 0.6% and 1.1% respectively in the maintenance trials and 0% and 0.6% in the acute trial. In the bipolar I disorder clinical trial, the incidence of hyperglycemia and diabetes were 0.8% and 0% respectively.

Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship
between atypical antipsychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies which did not include oral aripiprazole suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics. Because aripiprazole was not marketed at the time these studies were performed, it is not known if aripiprazole is associated with this increased risk. Precise risk estimates for hyperglycemia-related adverse events in patients treated with atypical antipsychotics are not available.

Patients should have baseline and periodic monitoring of blood glucose and body weight. Any patient treated with atypical antipsychotics should also be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control.

**Weight Gain**

Antipsychotic drugs have been associated with metabolic changes, including weight gain. Clinical monitoring of weight is recommended, (see ADVERSE REACTIONS, Weight).1,2

**Genitourinary**

**Priapism**

Although no cases of priapism were reported in clinical trials with ABILIFY MAINTENA, rare cases of priapism have been reported with antipsychotic use including oral aripiprazole. As with other psychotropic drugs, this adverse reaction did not appear to be dose-dependent and did not correlate with the duration of treatment.

**Hematologic**

In clinical trial and/or postmarketing experience, events of leukopenia/neutropenia have been reported temporally related to antipsychotic agents, including aripiprazole. Agranulocytosis has also been reported.

Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC) and history of drug-induced leukopenia/neutropenia. Patients with a history of a clinically significant low WBC or drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of ABILIFY MAINTENA should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.

Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Discontinue ABILIFY MAINTENA in patients with severe neutropenia (absolute neutrophil count <1x10^9/L) and follow their WBC counts until recovery, (see ADVERSE REACTIONS Abnormal Hematologic and Clinical Chemistry Findings).

**Venous thromboembolism**

Venous thromboembolism (VTE), including fatal pulmonary embolism, has been reported with antipsychotic drugs, including oral aripiprazole, in case reports and/or observational studies. When prescribing ABILIFY MAINTENA all potential risk factors for VTE should be identified and preventative measures undertaken.
Neurologic

Neuroleptic Malignant Syndrome (NMS)

Neuroleptic malignant syndrome is a potentially fatal symptom complex that has been reported in association with antipsychotic drugs, including oral aripiprazole.

Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase (CPK), myoglobinuria (rhabdomyolysis), and acute renal failure.

In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.), and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology.1

The management of NMS should include 1) immediate discontinuation of all antipsychotic drugs including ABILIFY MAINTENA and other drugs not essential to therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment for uncomplicated NMS.

If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of therapy should be very carefully considered. The patient should be carefully monitored, since recurrence of NMS has been reported.

Falls

Antipsychotics, including aripiprazole, may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy.

Tardive Dyskinesia

A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome is highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.

The risk of developing tardive dyskinesia and the likelihood that it will become irreversible increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increases. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.

There is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and, thereby, may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.
Given these considerations, ABILIFY MAINTENA should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that (1) is known to respond to antipsychotic drugs and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In such patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.

If signs and symptoms of tardive dyskinesia appear in a patient on ABILIFY MAINTENA, drug discontinuation should be considered. However, some patients may require treatment with ABILIFY MAINTENA despite the presence of the syndrome.

Extrapyramidal Symptoms
See ADVERSE REACTIONS, Extrapyramidal Symptoms.

Seizure/Convulsion
As with other antipsychotic drugs, ABILIFY MAINTENA should be used cautiously in patients with a history of seizures or with conditions that lower the seizure threshold. Conditions that lower the seizure threshold may be more prevalent in a population of 65 years or older.

Potential for Cognitive and Motor Impairment
ABILIFY MAINTENA, like other antipsychotics, may have the potential to impair judgment, thinking, or motor skills. Instruct patients to avoid operating hazardous machinery, including automobiles, until they are reasonably certain that therapy with ABILIFY MAINTENA does not affect them adversely.

Psychiatric

Suicide
The possibility of a suicide attempt is inherent in psychotic illnesses and close supervision and appropriate clinical management of high-risk patients should accompany drug therapy. As ABILIFY MAINTENA is to be administered by a Healthcare Professional, suicide due to an overdose is considered unlikely (see DOSAGE AND ADMINISTRATION).

Pathological Gambling and Other Impulse-Control Disorders
Post-marketing reports of pathological gambling have been reported in patients treated with aripiprazole. These reports suggest that patients can experience increased urges, particularly for gambling, and the inability to control these urges while taking aripiprazole. With regards to pathological gambling, patients with a prior history of gambling disorder may be at increased risk and should be monitored carefully. Other urges, reported very rarely, include: increased sexual urges, compulsive spending, binge or compulsive eating, and other impulsive and compulsive behaviours. Because patients may not recognize these behaviours as abnormal, it is important for prescribers to ask patients or their caregivers specifically about the development of new or increased gambling urges, sexual urges, compulsive spending, binge or compulsive eating, or other urges while being treated with aripiprazole. It should be noted that impulse-control symptoms can be associated with the underlying disorder; however, in some cases, although not all, urges were reported to have stopped when the dose was reduced or the medication was discontinued. Although impulse-control disorders have been reported very rarely, impulse-control disorders may result in harm to the patient and others if not recognized. Consider dose reduction or stopping the medication if patient develops such urges while taking aripiprazole.
Special Populations

Pregnant Women

Teratogenic effects
There are no adequate and well-controlled studies of aripiprazole in pregnant women. It is not known whether aripiprazole can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. In animal studies, aripiprazole demonstrated developmental toxicity, including possible teratogenic effects in rats and rabbits (see TOXICOLOGY).

Non-teratogenic effects
Neonates exposed to antipsychotic drugs, including aripiprazole, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization.

ABILIFY MAINTENA should not be used during pregnancy unless the expected benefits to the mother markedly outweigh the potential risks to the fetus.

Labor and Delivery
The effect of aripiprazole on labor and delivery in humans is unknown.

Nursing Women
Aripiprazole is excreted in human breast milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ABILIFY MAINTENA therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

Pediatrics (< 18 years of age)
Safety and effectiveness of ABILIFY MAINTENA in patients <18 years of age have not been evaluated and its use is not recommended.

Geriatrics (> 65 years of age)
The safety and efficacy of ABILIFY MAINTENA in patients 65 years of age or older have not been established. Caution should be used when treating geriatric patients.

In formal single-dose pharmacokinetic studies (with oral aripiprazole given in a single dose of 15 mg), aripiprazole clearance was 20% lower in elderly (>65 years) subjects compared to younger adult subjects (18 to 64 years). There was no detectable age effect, however, in the population pharmacokinetic analysis in schizophrenia patients. Also, the pharmacokinetics of aripiprazole after multiple doses in elderly patients appeared similar to that observed in young, healthy subjects.

Nevertheless, geriatric patients generally have decreased cardiac, hepatic and renal function, and more frequent use of concomitant medication. The presence of multiple factors that might increase the pharmacodynamic response to aripiprazole, or cause poorer tolerance or orthostasis, should lead to careful monitoring during the initial dosing period for elderly patients.
Use in Elderly Patients with Dementia

Overall mortality

**Elderly patients with dementia treated with oral atypical antipsychotic drugs showed increased mortality compared to placebo in a meta-analysis of 13 placebo-controlled trials of various atypical antipsychotic drugs.** In three placebo-controlled studies of aripiprazole in elderly patients with Alzheimer’s disease (n=938; mean age: 82.4 years; range: 56-99 years), the rate of death in aripiprazole-treated patients was 3.5%, compared to a rate of 1.7% in the placebo group during or within 30 days after termination from the double-blind phase of the studies. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. **ABILIFY MAINTENA is not indicated for the treatment of patients with dementia** (see WARNINGS AND PRECAUTIONS - Serious Warnings and Precautions).^3

Cerebrovascular Adverse Events, Including Stroke in Elderly Patients with Dementia

In placebo-controlled clinical studies with oral aripiprazole (two flexible dose and one fixed dose study) of elderly patients with dementia, there was an increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, in aripiprazole-treated patients. In the fixed-dose study, there was a statistically significant dose response relationship for cerebrovascular adverse events in patients treated with aripiprazole. Aripiprazole is not indicated for the treatment of patients with dementia (see WARNINGS AND PRECAUTIONS – Serious Warnings and Precautions).^3

Frequent Treatment Emergent Adverse Events in Elderly Patients with Dementia

In the placebo-controlled studies of elderly patients with dementia (n=595 treated with oral aripiprazole, n=343 treated with placebo), the following treatment-emergent adverse events (TEAEs) were reported at an incidence of ≥3% and aripiprazole incidence at least twice that for placebo: lethargy [placebo 2%, aripiprazole 5%], somnolence (including sedation) [placebo 3%, aripiprazole 8%], and incontinence (primarily, urinary incontinence) [placebo 1%, aripiprazole 5%], excessive salivation (placebo 0%, aripiprazole 4%), and lightheadedness (placebo 1%, aripiprazole 4%).

Dysphagia

Esophageal dysmotility and aspiration have been associated with antipsychotic drug use, including oral aripiprazole. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer’s dementia. Aripiprazole and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia. The emergence of difficulty swallowing or excessive somnolence could predispose patients to accidental injury or aspiration (see WARNINGS AND PRECAUTIONS - Serious Warnings and Precautions).
ADVERSE REACTIONS

**Adverse Drug Reaction Overview**

ABILIFY MAINTENA administered once monthly has been evaluated for safety in 2,649 adult patients in clinical trials in schizophrenia. Of the 2,649 adult schizophrenia patients exposed to ABILIFY MAINTENA, 2,567 patients have been treated with ABILIFY MAINTENA 400 mg/300 mg. Of the 2,649 patients exposed to ABILIFY MAINTENA, 1,316 patients have received at least 9 ABILIFY MAINTENA 400 mg/300 mg injections, (i.e., have been treated for at least 9 months), 941 patients have received at least 13 injections (i.e., have been treated for at least 12 months), and 632 patients received at least 26 injections (i.e., have been treated for 24 months).

ABILIFY MAINTENA has been evaluated for safety in 804 adult patients in clinical trials in bipolar I disorder, with approximately 530 patient-years of exposure to ABILIFY MAINTENA. A total of 419 patients were treated with ABILIFY MAINTENA for at least 7 consecutive injections (i.e., have been treated for at least 6 months) and 287 patients treated with ABILIFY MAINTENA had at least 13 consecutive injections (i.e., have been treated for at least 12 months).

**Clinical Trial Adverse Drug Reactions**

*Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.*

**Adverse Events Associated with Discontinuation of Treatment**

In the schizophrenia trials, overall adverse reactions that led to discontinuation were similar for the aripiprazole-treated and placebo-treated patients in both the acute and maintenance phase studies. During double-blind treatment phase of the maintenance trials (Controlled Trials), TEAEs resulting in discontinuation of trial medication were experienced by 40/534 (7.5%) ABILIFY MAINTENA 400 mg/300 mg subjects, 19/266 (7.1%) oral aripiprazole tablets 10-30 mg subjects, 24/131 (18.3%) aripiprazole IM depot 50 mg/25 mg subjects, and 18/134 (13.4%) placebo subjects. In the acute schizophrenia trial, there was overall little difference in the incidence of discontinuations due to adverse reactions between ABILIFY MAINTENA-treated (4%) and placebo-treated (8%) patients.

During the double-blind, placebo-controlled phase of the bipolar I disorder trial, fewer subjects experienced a TEAE resulting in discontinuation in the ABILIFY MAINTENA group (23/132; 17.4%) compared to the placebo group (34/133; 25.6%). The following TEAEs led to discontinuation of IMP in more than 1 subject in either treatment group (ABILIFY MAINTENA vs placebo): mania (2.3% vs 8.3%), bipolar I disorder (1.5% vs 6.0%), bipolar disorder (3.8% vs 3.0%), depression (3.0% vs 2.3%), akathisia (1.5% vs 0.0%), affective disorder (0.0% vs 1.5%), and major depression (0.0% vs 1.5%).

**Commonly Reported Adverse Events**

The adverse event profile was similar across placebo-controlled trials of ABILIFY MAINTENA, irrespective of the schizophrenia or bipolar I disorder indications.

In the schizophrenia trials, the most frequently observed adverse events (AEs) reported in ≥ 5% of patients in two double-blind pivotal maintenance clinical studies of ABILIFY MAINTENA were insomnia, weight increased, akathisia, headache, anxiety, weight decreased, nasopharyngitis and injection site pain. Overall these adverse events were mild to moderate in severity and were similar to those in the placebo treated
patients. Table 1 lists the adverse events in the maintenance clinical trials with ABILIFY MAINTENA that occurred at the frequency of 2% or greater.

Based on the placebo-controlled trial of ABILIFY MAINTENA in the acute phase of schizophrenia, the most commonly observed adverse events associated with the use of aripiprazole in patients (incidence of 5% or greater and aripiprazole incidence at least twice that for placebo) were increased weight, akathisia, sedation, and injection site pain. Table 2 presents the Adverse Events that occurred in the acute trials at a rate of 2% or greater.

In the bipolar I disorder trial of ABILIFY MAINTENA, none of the adverse events in the double-blind, placebo-controlled phase were reported at an incidence ≥ 5 % of patients AND at least twice the incidence of placebo. Based on the placebo-controlled trial of ABILIFY MAINTENA in patients with bipolar I disorder, the most frequently observed adverse events reported in ≥ 5 % of ABILIFY MAINTENA patients and greater than placebo were weight increased, akathisia, anxiety, restlessness, and somnolence. Table 3 presents the Adverse Events that occurred in the bipolar I disorder trials at a rate of 2% or greater.
Table 1 - Adverse Events occurring in 2% or more of subjects with schizophrenia in both placebo and active controlled maintenance clinical trials

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>ABILIFY MAINTENA 400 mg/300 mg (N = 534)</th>
<th>Oral Aripiprazole 10-30 mg (N = 266)</th>
<th>Aripiprazole IM Depot 50 mg/25 mg (N = 131)</th>
<th>Placebo (N = 134)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>Any TEAE</td>
<td>389 (72.8)</td>
<td>213 (80.1)</td>
<td>106 (80.9)</td>
<td>83 (61.9)</td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>15 (2.8)</td>
<td>9 (3.4)</td>
<td>6 (4.6)</td>
<td>3 (2.2)</td>
</tr>
<tr>
<td>Nausea</td>
<td>10 (1.9)</td>
<td>4 (1.5)</td>
<td>3 (2.3)</td>
<td>2 (1.5)</td>
</tr>
<tr>
<td>Toothache</td>
<td>14 (2.6)</td>
<td>13 (4.9)</td>
<td>3 (2.3)</td>
<td>3 (2.2)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>12 (2.2)</td>
<td>4 (1.5)</td>
<td>1 (0.8)</td>
<td>3 (2.2)</td>
</tr>
<tr>
<td>General Disorders and Administration Site Conditions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>11 (2.1)</td>
<td>9 (3.4)</td>
<td>2 (1.5)</td>
<td>1 (0.7)</td>
</tr>
<tr>
<td>Injection site pain</td>
<td>28 (5.2)</td>
<td>6 (2.3)</td>
<td>1 (0.8)</td>
<td>5 (3.7)</td>
</tr>
<tr>
<td>Infections and Infestations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bronchitis</td>
<td>7 (1.3)</td>
<td>5 (1.9)</td>
<td>5 (3.8)</td>
<td>2 (1.5)</td>
</tr>
<tr>
<td>Influenza</td>
<td>16 (3.0)</td>
<td>11 (4.1)</td>
<td>7 (5.3)</td>
<td>2 (1.5)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>31 (5.8)</td>
<td>25 (9.4)</td>
<td>9 (6.9)</td>
<td>7 (5.2)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>25 (4.7)</td>
<td>11 (4.1)</td>
<td>5 (3.8)</td>
<td>3 (2.2)</td>
</tr>
<tr>
<td>Investigations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood creatine phosphokinase</td>
<td>10 (1.9)</td>
<td>6 (2.3)</td>
<td>5 (3.8)</td>
<td>2 (1.5)</td>
</tr>
<tr>
<td>increased</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood pressure increased</td>
<td>6 (1.1)</td>
<td>1 (0.4)</td>
<td>0 (0.0)</td>
<td>3 (2.2)</td>
</tr>
<tr>
<td>Weight decreased</td>
<td>35 (6.6)</td>
<td>16 (6.0)</td>
<td>12 (9.2)</td>
<td>4 (3.0)</td>
</tr>
<tr>
<td>Weight increased</td>
<td>50 (9.4)</td>
<td>35 (13.2)</td>
<td>7 (5.3)</td>
<td>13 (9.7)</td>
</tr>
<tr>
<td>Metabolism and Nutrition Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>6 (1.1)</td>
<td>1 (0.4)</td>
<td>3 (2.3)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Musculoskeletal and Connective Tissue Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>15 (2.8)</td>
<td>4 (1.5)</td>
<td>0 (0.0)</td>
<td>1 (0.7)</td>
</tr>
<tr>
<td>Back pain</td>
<td>16 (3.0)</td>
<td>14 (5.3)</td>
<td>15 (11.5)</td>
<td>3 (2.2)</td>
</tr>
<tr>
<td>Pain in extremity</td>
<td>11 (2.1)</td>
<td>7 (2.6)</td>
<td>2 (1.5)</td>
<td>6 (4.5)</td>
</tr>
<tr>
<td>Nervous System Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Akathisia</td>
<td>43 (8.1)</td>
<td>18 (6.8)</td>
<td>11 (8.4)</td>
<td>8 (6.0)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>14 (2.6)</td>
<td>6 (2.3)</td>
<td>2 (1.5)</td>
<td>4 (3.0)</td>
</tr>
<tr>
<td>Headache</td>
<td>42 (7.9)</td>
<td>30 (11.3)</td>
<td>7 (5.3)</td>
<td>7 (5.2)</td>
</tr>
<tr>
<td>Sedation</td>
<td>13 (2.4)</td>
<td>3 (1.1)</td>
<td>1 (0.8)</td>
<td>1 (0.7)</td>
</tr>
<tr>
<td>Somnolence</td>
<td>14 (2.6)</td>
<td>12 (4.5)</td>
<td>2 (1.5)</td>
<td>1 (0.7)</td>
</tr>
<tr>
<td>Tremor</td>
<td>24 (4.5)</td>
<td>9 (3.4)</td>
<td>6 (4.6)</td>
<td>2 (1.5)</td>
</tr>
<tr>
<td>Psychiatric Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agitation</td>
<td>9 (1.7)</td>
<td>2 (0.8)</td>
<td>0 (0.0)</td>
<td>3 (2.2)</td>
</tr>
<tr>
<td>Anxiety</td>
<td>35 (6.6)</td>
<td>13 (4.9)</td>
<td>10 (7.6)</td>
<td>10 (7.5)</td>
</tr>
<tr>
<td>Depression</td>
<td>7 (1.3)</td>
<td>3 (1.1)</td>
<td>0 (0.0)</td>
<td>3 (2.2)</td>
</tr>
<tr>
<td>Insomnia</td>
<td>58 (10.9)</td>
<td>37 (13.9)</td>
<td>18 (13.7)</td>
<td>12 (9.0)</td>
</tr>
<tr>
<td>Psychotic disorder</td>
<td>16 (3.0)</td>
<td>8 (3.0)</td>
<td>8 (6.1)</td>
<td>9 (6.7)</td>
</tr>
<tr>
<td>Restlessness</td>
<td>16 (3.0)</td>
<td>4 (1.5)</td>
<td>4 (3.1)</td>
<td>3 (2.2)</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>10 (1.9)</td>
<td>5 (1.9)</td>
<td>10 (7.6)</td>
<td>5 (3.7)</td>
</tr>
<tr>
<td>Respiratory, Thoracic and Mediastinal Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cough</td>
<td>14 (2.6)</td>
<td>7 (2.6)</td>
<td>5 (3.8)</td>
<td>4 (3.0)</td>
</tr>
<tr>
<td>Vascular Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>7 (1.3)</td>
<td>4 (1.5)</td>
<td>4 (3.1)</td>
<td>3 (2.2)</td>
</tr>
</tbody>
</table>
Table 2- Adverse Events occurring in 2% or more of subjects with schizophrenia in the Acute Phase Placebo controlled clinical trial and greater than placebo.

<table>
<thead>
<tr>
<th>System organ class</th>
<th>MedDRA preferred term</th>
<th>Aripiprazole IM Depot 400/300mg (N=167)</th>
<th>Placebo (N=172)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal disorders</td>
<td>Abdominal discomfort</td>
<td>4 (2.4)</td>
<td>2 (1.2)</td>
</tr>
<tr>
<td></td>
<td>Constipation</td>
<td>16 (9.6)</td>
<td>12 (7.0)</td>
</tr>
<tr>
<td></td>
<td>Diarrhoea</td>
<td>5 (3.0)</td>
<td>4 (2.3)</td>
</tr>
<tr>
<td></td>
<td>Dry mouth</td>
<td>6 (3.6)</td>
<td>4 (2.3)</td>
</tr>
<tr>
<td></td>
<td>Toothache</td>
<td>9 (5.4)</td>
<td>8 (4.7)</td>
</tr>
<tr>
<td></td>
<td>Vomiting</td>
<td>5 (3.0)</td>
<td>2 (1.2)</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Fatigue</td>
<td>4 (2.4)</td>
<td>3 (1.7)</td>
</tr>
<tr>
<td></td>
<td>Injection site pain</td>
<td>9 (5.4)</td>
<td>1 (0.6)</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td>Upper respiratory tract infection</td>
<td>6 (3.6)</td>
<td>3 (1.7)</td>
</tr>
<tr>
<td>Investigations</td>
<td>Weight decreased</td>
<td>6 (3.6)</td>
<td>4 (2.3)</td>
</tr>
<tr>
<td></td>
<td>Weight increased</td>
<td>28 (16.8)</td>
<td>12 (7.0)</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>Arthralgia</td>
<td>6 (3.6)</td>
<td>2 (1.2)</td>
</tr>
<tr>
<td></td>
<td>Back pain</td>
<td>7 (4.2)</td>
<td>4 (2.3)</td>
</tr>
<tr>
<td></td>
<td>Musculoskeletal pain</td>
<td>5 (3.0)</td>
<td>2 (1.2)</td>
</tr>
<tr>
<td></td>
<td>Myalgia</td>
<td>6 (3.6)</td>
<td>1 (0.6)</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Akathisia</td>
<td>19 (11.4)</td>
<td>6 (3.5)</td>
</tr>
<tr>
<td></td>
<td>Dizziness</td>
<td>6 (3.6)</td>
<td>3 (1.7)</td>
</tr>
<tr>
<td></td>
<td>Sedation</td>
<td>9 (5.4)</td>
<td>2 (1.2)</td>
</tr>
<tr>
<td></td>
<td>Tremor</td>
<td>5 (3.0)</td>
<td>1 (0.6)</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>Insomnia</td>
<td>8 (4.8)</td>
<td>8 (4.7)</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Cough</td>
<td>10 (6.0)</td>
<td>10 (5.8)</td>
</tr>
<tr>
<td></td>
<td>Nasal congestion</td>
<td>4 (2.4)</td>
<td>2 (1.2)</td>
</tr>
</tbody>
</table>
Table 3- Adverse Events occurring in 2% or more of subjects with bipolar I disorder in the placebo controlled clinical trial and greater than placebo.

<table>
<thead>
<tr>
<th>System organ class</th>
<th>MedDRA preferred term</th>
<th>ABILIFY MAINTENA 400/300mg (N=132)</th>
<th>Placebo (N=133)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and Lymphatic System Disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anaemia</td>
<td></td>
<td>3 (2.3)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Eye Disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vision blurred</td>
<td></td>
<td>3 (2.3)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td>Constipation</td>
<td>4 (3.0)</td>
<td>4 (3.0)</td>
</tr>
<tr>
<td></td>
<td>Dry mouth</td>
<td>4 (3.0)</td>
<td>3 (2.3)</td>
</tr>
<tr>
<td></td>
<td>Salivary hypersecretion</td>
<td>3 (2.3)</td>
<td>3 (2.3)</td>
</tr>
<tr>
<td>Infections and Infestations</td>
<td>Bronchitis</td>
<td>3 (2.3)</td>
<td>2 (1.5)</td>
</tr>
<tr>
<td></td>
<td>Influenza</td>
<td>3 (2.3)</td>
<td>2 (1.5)</td>
</tr>
<tr>
<td></td>
<td>Sinusitis</td>
<td>5 (3.8)</td>
<td>1 (0.8)</td>
</tr>
<tr>
<td></td>
<td>Urinary tract infection</td>
<td>4 (3.0)</td>
<td>2 (1.5)</td>
</tr>
<tr>
<td>Injury, Poisoning and Procedural</td>
<td>Procedural Pain</td>
<td>4 (3.0)</td>
<td>1 (0.8)</td>
</tr>
<tr>
<td>Complications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investigations</td>
<td>Blood creatine phosphokinase increased</td>
<td>3 (2.3)</td>
<td>1 (0.8)</td>
</tr>
<tr>
<td>Metabolism and Nutrition Disorders</td>
<td>Weight increased</td>
<td>31 (23.5)</td>
<td>24 (18.0)</td>
</tr>
<tr>
<td></td>
<td>Increased appetite</td>
<td>4 (3.0)</td>
<td>1 (0.8)</td>
</tr>
<tr>
<td>Nervous System Disorders</td>
<td>Akathisia</td>
<td>28 (21.2)</td>
<td>17 (12.8)</td>
</tr>
<tr>
<td></td>
<td>Somnolence</td>
<td>6 (4.5)</td>
<td>1 (0.8)</td>
</tr>
<tr>
<td></td>
<td>Tremor</td>
<td>3 (2.3)</td>
<td>2 (1.5)</td>
</tr>
<tr>
<td>Psychiatric Disorders</td>
<td>Anxiety</td>
<td>9 (6.8)</td>
<td>6 (4.5)</td>
</tr>
<tr>
<td></td>
<td>Bipolar Disorder</td>
<td>5 (3.8)</td>
<td>5 (3.8)</td>
</tr>
<tr>
<td></td>
<td>Depression</td>
<td>4 (3.0)</td>
<td>3 (2.3)</td>
</tr>
<tr>
<td></td>
<td>Insomnia</td>
<td>10 (7.6)</td>
<td>10 (7.5)</td>
</tr>
<tr>
<td></td>
<td>Libido decreased</td>
<td>3 (2.3)</td>
<td>2 (1.5)</td>
</tr>
<tr>
<td></td>
<td>Restlessness</td>
<td>6 (4.5)</td>
<td>5 (3.8)</td>
</tr>
</tbody>
</table>
Injection Site Adverse Events

The investigator rated pain, redness, swelling, and induration at the injection site at the same visits where subjects assessed pain using a Visual Analog Scale (VAS; 0 mm = no pain to 100 mm = unbearably painful). Analyses of injection site assessments (investigator-rated and subject-reported VAS) were performed to evaluate the safety/tolerability of ABILIFY MAINTENA.

Injection site assessments were completed after all injections during the ABILIFY MAINTENA schizophrenia and bipolar I disorder trials. The injection site adverse drug reaction profile was consistent across schizophrenia and bipolar studies. Across long-term trials, patient evaluations of injection site pain based on the VAS scale tended to lessen in frequency and intensity over time. In addition, overall, reactions were reported to be of mild to moderate severity.

During the double-blind phase of schizophrenia maintenance studies, 37/534 (6.9%) ABILIFY MAINTENA 400 mg/300 mg subjects, 7/266 (2.6%) oral aripiprazole tablets 10-30 mg subjects, 1/131 (0.8%) aripiprazole IM depot 50 mg/25 mg IM subjects, and 5/134 (3.7%) placebo subjects experienced TEAEs related to the injection site.

In the data from the acute phase double-blind placebo controlled trial with ABILIFY MAINTENA in patients with schizophrenia, the percent of patients reporting any injection site-related adverse reaction was 5.4% for ABILIFY MAINTENA-treated patients. The mean intensity of injection pain reported by subjects using a visual analog scale (0=no pain to 100=unbearably painful) was minimal in subjects receiving ABILIFY MAINTENA (7.1 after first injection, and 7.7 after last injection).

In the data from the double-blind, placebo-controlled phase in patients with bipolar I disorder, the percentage of patients reporting injection site-related adverse reactions was similar between ABILIFY MAINTENA (0.8%) and placebo (1.5%).

### Table 4 Investigator assessments of pain, swelling and induration at the injection site and Patient VAS scores

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>Absence of Investigator Rated Pain, Redness, Swelling, and Induration at the Injection Site (% of patients)*</th>
<th>Mean VAS (patient rated pain from 0 – 100mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>First Injection</td>
<td>Last Injection</td>
</tr>
<tr>
<td><strong>38-week ABILIFY MAINTENA double-blind, active-controlled trial in adult patients with schizophrenia</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABILIFY MAINTENA 400 mg/300 mg (n=265)</td>
<td>81.4 – 98.1</td>
<td>88.3 – 98.9</td>
</tr>
<tr>
<td>Oral aripiprazole 10-30 mg (n=266)</td>
<td>83.3 – 98.5</td>
<td>90.2 – 99.6</td>
</tr>
<tr>
<td>Aripiprazole IM Depot 50 mg/25 mg (n=131)</td>
<td>90.7 – 99.2</td>
<td>90.0 – 99.2</td>
</tr>
<tr>
<td><strong>52-week ABILIFY MAINTENA double-blind, placebo-controlled trial in adult patients with schizophrenia</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IM Depot Stabilization Phase (Open Label)**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABILIFY MAINTENA 400 mg/300 mg (n=403)</td>
<td>75.3 – 96.2</td>
<td>77.3 – 97.0</td>
</tr>
<tr>
<td><strong>Double-blind, Placebo-controlled Phase</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABILIFY MAINTENA 400 mg/300 mg (n=269)</td>
<td>80.1 – 98.1</td>
<td>84.4 – 98.5</td>
</tr>
<tr>
<td>Placebo (n=134)</td>
<td>72.2 – 97.7</td>
<td>77.3 – 97.7</td>
</tr>
</tbody>
</table>
### Absence of Investigator Rated Pain, Redness, Swelling, and Induration at the Injection Site (% of patients)

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>Dose</th>
<th>First Injection</th>
<th>Last Injection</th>
<th>Mean VAS (patient rated pain from 0 – 100mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>First Injection</td>
<td>Last Injection</td>
<td>First Injection</td>
</tr>
<tr>
<td>12-week ABILIFY MAINTENA double-blind, placebo-controlled trial in the acute phase of schizophrenia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABILIFY MAINTENA</td>
<td>400 mg/300 mg (n=167)</td>
<td>95.1-100</td>
<td>99.2-100</td>
<td>7.1</td>
</tr>
<tr>
<td>Placebo (n=172)</td>
<td></td>
<td>94.7-100</td>
<td>98.4-100</td>
<td>5.7</td>
</tr>
<tr>
<td>52-week ABILIFY MAINTENA double-blind, placebo-controlled trial in patients with bipolar I disorder</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABILIFY MAINTENA</td>
<td>400 mg/300 mg (n=132)</td>
<td>81.8-100</td>
<td>87.1-100</td>
<td>5.2</td>
</tr>
<tr>
<td>Placebo (n=133)</td>
<td></td>
<td>81.2-100</td>
<td>85.0-100</td>
<td>5.7</td>
</tr>
</tbody>
</table>

*Range of percent is based on rating in the 4 domains (pain, redness, swelling, and induration)

**The open-label analyses were done to understand the injection site reaction parameters after initiation of ABILIFY MAINTENA as well as during its continued use in the double-blind, placebo-controlled phase.

In an open label study comparing bioavailability of ABILIFY MAINTENA administered in the deltoid or gluteal muscle, injection site related reactions were observed in both groups at approximately equal rates and the majority were mild and improved on subsequent injections.

### Extrapyramidal Symptoms (EPS)

The table below presents the percentage of patients experiencing treatment emergent EPS and EPS related events during the double-blind phases of the 38-and 52-week trials in schizophrenia.

**Table 5 Patients experiencing EPS and EPS related Events in the schizophrenia maintenance trials**

<table>
<thead>
<tr>
<th>Treatment Emergent EPS and EPS related events</th>
<th>ABILIFY MAINTENA 400 mg/300 mg</th>
<th>Oral aripiprazole 10-30 mg</th>
<th>Aripiprazole IM Depot 50 mg/25 mg (n=131)</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>18.4%</td>
<td>11.7%</td>
<td>12.2%</td>
<td>9.7%</td>
<td></td>
</tr>
<tr>
<td>Akathisia</td>
<td>8.2%</td>
<td>6.8%</td>
<td>8.4%</td>
<td>6.0%</td>
</tr>
<tr>
<td>Parkinsonism</td>
<td>6.9%</td>
<td>4.1%</td>
<td>5.3%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

There was minimal variation in EPS symptoms during the double-blind phases of the schizophrenia trials, as assessed by mean changes from baseline in the Simpson Angus Scale (SAS), Abnormal Involuntary Movement Scale (AIMS), and Barnes Akathisia Rating Scale (BARS) rating scales. Although there were statistically significant differences between the mean change from baseline in the BARS global score between ABILIFY MAINTENA 400 mg/300 mg and oral aripiprazole tablets 10-30 mg (Weeks 8 and 38) and between ABILIFY MAINTENA 400 mg/300 mg and aripiprazole IM depot 50 mg/25 mg (Week 8, Week 12 and Week 36), the mean changes were not considered to be clinically relevant.

Similar results were observed in the 12-week placebo controlled study in the acute phase of schizophrenia, with akathisia occurring in 11.4% of the subjects on ABILIFY MAINTENA compared to 3.5% of placebo subjects and parkinsonism occurring in 5.4% of ABILIFY MAINTENA subjects compared to 2.3% of placebo subjects.

During the double-blind, placebo-controlled phase of the bipolar I disorder trial, 36/132 (27.3%) ABILIFY MAINTENA-treated subjects and 22/133 (16.5%) placebo-treated subjects had treatment-emergent EPS and
EPS-related AEs. In the ABILIFY MAINTENA (vs. placebo) group, EPS and EPS-related events reported by ≥ 2% of subjects were akathisia and psychomotor hyperactivity events (22.0% vs 12.8%), parkinsonism events (5.3% vs 3.8%), dyskinetic (2.3% vs 1.5%), and dystonic events (2.3% vs 0.0%).

The most frequently reported treatment-emergent EPS and EPS-related AE was akathisia with 28/132 (21.2%) ABILIFY MAINTENA-treated subjects and 17/133 (12.8%) placebo-treated subjects experiencing an event. One ABILIFY MAINTENA-treated and no placebo-treated subjects experienced an SAE of akathisia and 2 ABILIFY MAINTENA-treated subjects were discontinued due to akathisia. There were no other EPS-related SAEs and no other TEAEs leading to discontinuation reported.

**Dystonia**

*Class Effect*-Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

**Weight**

One placebo-controlled trial with ABILIFY MAINTENA was conducted in hospitalized patients in the acute phase of schizophrenia, the mean change in body weight was +2.8 kg (N=144) in the ABILIFY MAINTENA-treated patients and +0.8 kg (N=141) in the placebo-treated patients, as assessed in patients with a median exposure of 85 days and a post baseline weight result at the last visit. The incidence of weight gain of ≥ 7% from baseline to last visit was 22% for the ABILIFY MAINTENA 400 mg/300 mg group, and 9% for the placebo group.

During double-blind treatment in the maintenance schizophrenia trials (Controlled Trials), TEAEs related to weight were reported for 87/534 (16.3%) ABILIFY MAINTENA 400 mg/300 mg subjects, 52/266 (19.5%) oral aripiprazole tablets 10-30 mg subjects, 19/131 (14.5%) aripiprazole IM depot 50 mg/25 mg subjects, and 17/134 (12.7%) placebo subjects. TEAEs related to weight that were reported included increased weight, decreased weight, overweight, and edema.

During the double-blind, active-controlled phase of the 38-week ABILIFY MAINTENA schizophrenia trial, the incidence of weight gain of ≥ 7% from baseline to last visit was 9.5% for the ABILIFY MAINTENA 400 mg/300 mg group, 11.7% for oral aripiprazole tablets 10-30 mg group and 4.6% for the aripiprazole IM depot 50 mg/25 mg group. The incidence of weight loss of ≥ 7% from baseline to last visit was 10.2% for ABILIFY MAINTENA 400 mg/300 mg, 4.5% for oral aripiprazole tablets 10-30 mg, and 9.9% for aripiprazole IM depot 50 mg/25 mg. During double-blind treatment, mean change in body weight from baseline to last visit was -0.2kg for ABILIFY MAINTENA, +0.7kg for oral aripiprazole tablets and -1.1 for aripiprazole IM depot 50 mg/25 mg. Overall in the maintenance clinical trials there was no difference in the incidence of weight gain between ABILIFY MAINTENA and placebo.

During the double-blind, placebo-controlled phase of the 52-week ABILIFY MAINTENA schizophrenia trial, the incidence of weight gain of ≥ 7% from baseline to last visit was similar between ABILIFY MAINTENA and placebo: 6.4% for the ABILIFY MAINTENA 400 mg/300 mg group and 5.2% for the placebo group. The incidence of weight loss of ≥ 7% from baseline to last visit was 6.4% for the ABILIFY MAINTENA 400 mg/300 mg group and 6.7% for the placebo group. During double-blind treatment, mean change in body weight from baseline to last visit was -0.2kg for ABILIFY MAINTENA and -0.4kg for placebo.

During the double-blind, placebo-controlled phase of the bipolar I disorder trial, the incidence of weight gain ≥7% at any time was reported for 18.0% for ABILIFY MAINTENA-treated subjects and 12.9% for
placebo-treated subjects; the incidence of weight loss ≥ 7% at any time was reported for 9.4% ABILIFY MAINTENA-treated subjects and 12.1% placebo-treated subjects. At the last visit, the incidence of potentially clinically relevant weight gain was 13.3% ABILIFY MAINTENA-treated subjects and 12.1% placebo-treated subjects; the incidence of weight loss ≥ 7% at last visit was reported for 5.5% ABILIFY MAINTENA-treated subjects and 10.6% placebo-treated subjects. The mean change (SD) from baseline at Week 52 was 1.3 (5.9) kg for ABILIFY MAINTENA-treated and 1.5 (6.1) kg for placebo-treated subjects; and at last visit was 0.9 (5.3) kg for ABILIFY MAINTENA-treated and 0.0 (5.9) kg for placebo-treated subjects.

**QT Interval**
During double-blind treatment in patients with schizophrenia, 1/534 (0.2%) ABILIFY MAINTENA 400 mg/300 mg subjects had a TEAE related to QT interval change (prolonged ECG QT).

In the double-blind, placebo-controlled phase of the bipolar I disorder trial and the open-label trial, there were no QT interval-related TEAEs reported.

In the clinical trials of treatment with ABILIFY MAINTENA across indications, the incidence of QT prolongation was comparable to placebo. As with other antipsychotics, aripiprazole should be used with caution in patients with a family history of QT prolongation.

**Prolactin**
Changes in prolactin levels were comparable across trials, irrespective of indication (schizophrenia or bipolar I disorder), and there were no clinically relevant mean changes from baseline to the last visit with regard to prolactin levels during the double-blind treatment phase of either trial.

In the double-blind active-controlled phase of the 38-week schizophrenia trial, from baseline to last visit, there was a mean decrease in prolactin levels in the ABILIFY MAINTENA 400 mg/300 mg group (−0.33 ng/mL) compared with a mean increase in the oral aripiprazole tablets 10-30 mg group (0.79 ng/mL) and aripiprazole IM depot 50 mg/25 mg (1.11 ng/mL) groups. The incidence for ABILIFY MAINTENA 400 mg/300 mg patients with prolactin levels >1 time the upper limit of normal range (ULN) at any assessment was 5.4% compared with 3.5% of oral aripiprazole tablets 10-30 mg, and 4.7% of aripiprazole IM depot 50 mg/25 mg patients, with a higher incidence in male patients than female patients in each treatment group.

In the double-blind placebo-controlled phase of the 52-week schizophrenia trial, from baseline to last visit, there was a mean decrease in prolactin levels in the ABILIFY MAINTENA 400 mg/300 mg group (−0.38 ng/mL) compared with a mean increase in the placebo group (1.67 ng/mL). The incidences of ABILIFY MAINTENA 400 mg/300 mg patients with prolactin levels >1 time the upper limit of normal range (ULN) was 1.9% compared to 7.1% for placebo patients.

In the double-blind, placebo-controlled phase of the bipolar I disorder trial, the mean changes from baseline to last visit in prolactin were minimal in the ABILIFY MAINTENA 400 mg/300 mg group (0.15 ng/mL) compared to placebo (3.00 ng/mL) and none of the changes were considered to be clinically meaningful. There were no clinically meaningful differences in the incidence of prolactin levels above the ULN between treatment groups and no incidence of > 3 × ULN reported during the double-blind, phase of this trial. No clinically meaningful differences in shifts in prolactin between treatment groups or gender were reported. During the double-blind phase, no ABILIFY MAINTENA-treated and 0.8% of placebo-treated subjects experienced the prolactin-related TEAE of hyperprolactinaemia.
Less Common Clinical Trial Adverse Drug Reactions <2%

All reported events in the ABILIFY MAINTENA group during the randomisation phase of the schizophrenia clinical trials, reported by less than 2% of subjects, and at least as frequently in the placebo group are listed below.

**Blood and Lymphatic System Disorders:** Anemia, bicytopenia, lymphadenopathy, neutropenia, thrombocytopenia.

**Cardiac Disorders:** Acute myocardial infarction, atrioventricular blocks first degree, cardiac failure congestive, ventricular extrasystoles.

**Ear and Labyrinth disorders:** Deafness, vertigo.

**Eye Disorders:** Conjunctivitis allergic, eye irritation, eye pain, eyelid ptosis, oculogyric crisis, vision blurred.

**Gastrointestinal disorders:** Abdominal pain, abdominal pain upper, anorectal discomfort, aphthous stomatitis, colitis, dental caries, diverticulum, dyspepsia, dysphagia, frequent bowel movements, gastritis, gastroesophageal reflux disease, gingival oedema, gingival pain, gingivitis, haemorrhoids, inguinal hernia, loose tooth, periodontitis, poor dental condition, salivary hypersecretion, tongue disorder, tooth impacted, tooth loss.

**General disorders and administration site conditions:** Asthenia, chest discomfort, gait disturbance, influenza like illness, infusion site haematoma, infusion site swelling, injection site discomfort, injection site pruritus, injection site induration, injection site reaction, injection site swelling, pain, sluggishness, suprapubic pain, thirst, vessel puncture site haematoma, vessel puncture site pain.

**Hepatobiliary disorders:** Cholecystitis chronic, cholelithiasis, hepatic cirrhosis, hepatic steatosis, hepatosplenomegaly.

**Immune System Disorders:** Drug hypersensitivity.

**Infections and Infestations:** Acarodermatitis, anal abscess, appendicitis perforated, cellulitis, cystitis, ear infection, Escherichia UTI, folliculitis, fungal infection, fungal skin infection, furuncle, gastroenteritis, gastroenteritis viral, herpes virus infection, herpes zoster, hordeolum, impetigo, lice infestation, localised infection, mastitis, oral candidiasis, pharyngitis, pharyngitis streptococcal, pilonidal cyst, pneumonia, respiratory tract infection, viral rhinitis, subcutaneous abscess, tinea pedis, tooth abscess, tooth infection, urinary tract infections, vaginal infection, varicella, viral infection, vulvovaginal mycotic infection.

**Injury, poisoning and procedural complications:** Accident, ankle fracture, carbon monoxide poisoning, contusion, drug toxicity, excoriation, face injury, fall, foot fracture, gunshot wound, injury, joint dislocation, joint sprain, multiple injuries, muscle injury, muscle strain, procedural pain, radius fracture, skeletal injury, skin laceration, thermal burn, tooth fracture, wound.

**Investigations:** Alkaline phosphatase increased, bilirubin increased, blood insulin increased, cholesterol decreased, glucose decreased, glucose increased, lactate dehydrogenase increased, triglycerides decreased, triglycerides increased, electrocardiogram abnormal, electrocardiogram QT prolonged, electrocardiogram T wave amplitude decreased, electrocardiogram T wave inversion, gamma-glutamyltransferase increased, glucose urine present, glycosylated haemoglobin increased, heart rate decreased, hepatic enzyme increased, liver function test abnormal, neutrophil count decreased, protein urine, waist circumference increased, white blood cell count decreased, white blood cells urine.
Metabolism and nutrition disorders: appetite disorder, diabetes mellitus, gout, hypercholesterolaemia, hyperglycaemia, hyperinsulinaemia, hyperlipidaemia, hypertriglyceridaemia, hyperuricaemia, hypoglycaemia, increased appetite, overweight, type 2 diabetes mellitus.

Musculoskeletal and connective tissue disorders: arthritis, joint swelling, muscle rigidity, muscle spasm, muscle tightness, muscle twitching, musculoskeletal pain, myalgia, nuchal rigidity, rotator cuff syndrome, trismus.

Neoplasms benign malignant and unspecified: basal cell carcinoma, breast fibroma, pancreatic carcinoma.

Nervous system disorders: bradykinesia, cogwheel rigidity, disturbance in attention, drooling, dyskinesia, dystonia, extrapyramidal disorder, hypersomnia, hypoaesthesia, migraine, movement disorder, parkinsonism, parosmia, poor quality sleep, psychomotor hyperactivity, restless leg syndrome, sinus headache, syncope, tension headache.

Psychiatric Disorders: abnormal dreams, affect lability, apathy, bruxism, bulimia nervosa, delusion, dysphoria, hallucination auditory, hypersexuality, hypoosomnia, libido decreased, middle insomnia, mood altered, nightmare, panic attack, panic reaction, sleep disorder, suicidal ideation, suicide attempt, tension.

Renal and Urinary Disorders: glycosuria, micturition urgency, nephrolithiasis, pollakiuria.

Reproductive system and breast disorders: adnexa uteri pain, breast mass, breast tenderness, erectile dysfunction, galactorrhoea, gynaecomastia, ovarian cyst, vulvovaginal dryness.

Respiratory Thoracic and Mediastinal disorders: acute respiratory distress syndrome, dysphonia, dyspnœa, epistaxis, nasal septum deviation, oropharyngeal pain, paranasal sinus hypersecretion, respiratory tract congestion, rhinalgia, rhinitis allergic, sinus congestion, wheezing.

Skin and Subcutaneous tissue disorders: acne, blister, dry skin, eczema, erythema, hyperkeratosis, pruritus, psoriasis, rash macula, rosacea, skin induration, skin lesion, skin striae, urticaria.

Vascular Disorders: orthostatic hypertension.

Adverse Events reported with Oral Aripiprazole

Short-Term, Placebo-Controlled Trials of Adult Patients with Schizophrenia

Based on a pool of five placebo-controlled trials (four 4-week and one 6-week) in which aripiprazole was administered orally in doses ranging from 2 to 30 mg/day the only commonly observed adverse event associated with the use of oral aripiprazole in patients with schizophrenia (incidence of 5% or greater and aripiprazole incidence at least twice that for placebo) was akathisia (placebo 4%; aripiprazole 8%).

Long-Term, Double-Blind, Placebo-Controlled Trials in Adult Patients with Schizophrenia

The adverse events reported in a 26-week, double-blind trial comparing oral aripiprazole and placebo in adult patients with schizophrenia were generally consistent with those reported in the short-term, placebo-controlled trials, except for a higher incidence of tremor [8% (12/153) for oral aripiprazole vs. 2% (3/153) for placebo]. In this study, the majority of the cases of tremor were of mild intensity (8/12 mild and 4/12 moderate), occurred early in therapy (9/12 ≤49 days), and were of limited duration (7/12 ≤10 days). Tremor infrequently led to discontinuation (<1%) of oral aripiprazole. In addition, in a long-term (52-week), active-controlled study, the incidence of tremor for oral aripiprazole was 5% (40/859).
Short-Term, Placebo-Controlled Trials of Adult Patients with Bipolar Disorder

The following findings are based on a pool of 3-week, placebo-controlled, bipolar mania trials in which aripiprazole was administered orally at doses of 15 or 30 mg/day. Overall, in patients with bipolar mania, there was little difference in the incidence of discontinuation due to adverse events between aripiprazole-treated (11%) and placebo-treated (10%) patients. The types of adverse events that led to discontinuation were similar between the aripiprazole and placebo-treated patients. Akathisia, the most common adverse event leading to discontinuation in the aripiprazole group, led to withdrawal of 2% of aripiprazole-treated patients and 0.3% of patients on placebo. Commonly reported adverse events associated with the use of aripiprazole in patients with bipolar mania (incidence of 5% or greater and aripiprazole incidence at least twice that of placebo) was, for aripiprazole and placebo (respectively): akathisia: 13/917 and 4/753, sedation: 8/917 and 3/753, restlessness: 6/917 and 2/753, and extrapyramidal disorder: 5/917 and 2/753.

Abnormal Hematologic and Clinical Chemistry Findings

No clinically relevant mean changes from baseline in serum chemistry, hematology, urinalysis, or other laboratory test (insulin, fasting insulin) results were observed during any of the clinical trials with ABILIFY MAINTENA.

In both schizophrenia maintenance trials differences in the mean (± SD) change from the double-blind treatment phase baseline at the last visit in WBC, fasting glucose, lipids, and CPK levels were negligible between the ABILIFY MAINTENA 400 mg/300 mg group, and oral aripiprazole tablets 10-30 mg group, aripiprazole IM depot 50 mg/25 mg group or placebo groups and were considered to be of no clinical relevance. Mean changes in total CPK has been associated with NMS, and higher percentages of elevated creatine phosphokinase have been observed in oral aripiprazole-treated adult patients compared to placebo-treated patients in short-term and long-term clinical trials; however mean decreases were noted for ABILIFY MAINTENA 400 mg/300 mg in the active controlled trial and the differences between the ABILIFY MAINTENA and placebo groups were negligible in the placebo controlled maintenance trial. In the acute placebo controlled trial no clinically relevant mean changes from baseline in serum chemistry, hematology, urinalysis or other laboratory tests were observed during the acute treatment phase.

In the bipolar I disorder placebo-controlled and open label trials, no subject met the criteria for Hy’s law relative to laboratory values of potential clinical relevance.

In clinical studies of oral aripiprazole, in a long-term (26-week) placebo-controlled trial in adult patients with schizophrenia there were no clinically important differences between the aripiprazole and placebo patients in the mean change from baseline in prolactin, fasting glucose, triglyceride, HDL, LDL, and total cholesterol measurements. Higher percentages of elevated creatine phosphokinase were observed in aripiprazole-treated adult patients compared to placebo-treated patients in short-term and long-term clinical trials. The most common AEs that were temporally associated with elevated CPK levels were musculoskeletal stiffness, myalgia, chest pain, fall, and muscle rigidity.

Post-Market Adverse Drug Reactions

The following adverse reactions have been identified during post-approval use of oral aripiprazole or ABILIFY MAINTENA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

The adverse events presented in Table 6 were reported during the post-marketing use of aripiprazole.

<table>
<thead>
<tr>
<th>Table 6 Post-marketing events- aripiprazole</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Psychiatric Disorders</strong>:</td>
</tr>
<tr>
<td><em>Very Rare</em>: Pathological gambling, Hypersexuality, Impulse-control disorders</td>
</tr>
</tbody>
</table>

**Psychiatric Disorders**: Pathological gambling, Hypersexuality, Impulse-control disorders
## Skin and Subcutaneous Tissue Disorders:

**Very Rare:** Allergic reaction (e.g., anaphylactic reaction, angioedema, laryngospasm, oropharyngeal spasm), Hyperhidrosis, Alopecia

## Investigations:

**Very Rare:** Blood glucose increased, Blood glucose fluctuation, Increased Alanine Aminotransferase (ALT or SGPT), Increased Aspartate Aminotransferase (AST or SGOT), Increased Gamma-glutamyltransferase (GGT)

## Hepatobiliary Disorders:

**Unknown:** Hepatic failure  
**Very Rare:** Hepatitis, Jaundice

## Nervous System Disorders:

**Very Rare:** Speech disorder, Grand mal convulsion

## Eye Disorders

**Very Rare:** Diplopia

## Gastrointestinal Disorders

**Very Rare:** Pancreatitis

## Renal and Urinary Disorders

**Very Rare:** Urinary retention

## Metabolism and Nutrition Disorders

**Very Rare:** Hyponatremia, Anorexia

## Respiratory, Thoracic, and Mediastinal Disorders

**Very Rare:** Hiccups

Although a causal relationship has not been established, cases of suicide attempt, suicidal ideation, and completed suicide have been reported post marketing.

As with other antipsychotics, sudden death, torsades de pointes, ventricular tachycardia, arrhythmia, cardiopulmonary arrest and QT prolongation have been reported during treatment with oral aripiprazole. These events during aripiprazole treatment have been very rare or isolated. Many of the patients had pre-existing cardiovascular disease, were on concomitant medications known to prolong the QT interval, had risk factors for QT prolongation, took an overdose of oral aripiprazole, and/or were morbidly obese. Very rarely, QT prolongation has been reported in the absence of confounding factors.

Isolated cases of Serotonin Syndrome have been reported with the concomitant use of aripiprazole and serotonergic drugs such as Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) and Selective Serotonin Reuptake Inhibitor (SSRI).

Complex sleep-related behaviours such as somnambulism and sleep-related eating disorder have been associated with the use of atypical antipsychotic drugs, including aripiprazole.

In clinical trial and/or post-marketing experience, events of leukopenia/neutropenia have been reported temporally related to antipsychotic agents, including aripiprazole. Agranulocytosis has also been reported. Therefore, it is recommended that patients have their complete blood count (CBC) tested prior to starting ABILOFY MAINTENA and then periodically throughout treatment (see WARNINGS AND PRECAUTIONS - Hematologic).

Atypical antipsychotic drugs, including aripiprazole, have been associated with cases of sleep apnea, with or without concomitant weight gain. In patients who have a history of or are at risk for sleep apnea, aripiprazole should be prescribed with caution.
DRUG INTERACTIONS

Overview

No specific drug interaction studies have been performed with ABILIFY MAINTENA. The information below is obtained from studies with oral aripiprazole.

Due to its $\alpha_1$-adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.

Given the primary CNS effects of aripiprazole, caution should be used when aripiprazole is administered in combination with alcohol or other CNS medicinal products with overlapping adverse reactions such as sedation.

If aripiprazole is administered concomitantly with medicinal products known to cause QT prolongation or electrolyte imbalance, caution should be used.

Drug-Drug Interactions

Potential for other drugs to affect aripiprazole

Aripiprazole is metabolised by multiple pathways involving the CYP2D6 and CYP3A4 enzymes but not CYP1A enzymes. Thus, no dosage adjustment is required for smokers.

Quinidine and other strong CYP2D6 inhibitors

After oral administration of aripiprazole to healthy subjects, a strong inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC by 107%, while Cmax was unchanged. The AUC and Cmax of dehydro-aripiprazole, the active metabolite, decreased by 32% and 47%, respectively. Other strong inhibitors of CYP2D6, such as fluoxetine, paroxetine, and bupropion may be expected to have similar effects (see DOSAGE AND ADMINISTRATION Section Table 7 for dose adjustments).

Ketoconazole and other strong CYP3A4 inhibitors

After oral administration of aripiprazole to healthy subjects, a strong inhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and Cmax by 63% and 37%, respectively. The AUC and Cmax of dehydro-aripiprazole increased by 77% and 43%, respectively. Other strong inhibitors of CYP3A4, such as itraconazole, and HIV protease inhibitors may be expected to have similar effects (see DOSAGE AND ADMINISTRATION Section Table 7 for dose adjustments), weaker inhibitors (erythromycin, grapefruit juice) have not been studied.

Upon discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of ABILIFY MAINTENA should be increased to the dose prior to the initiation of the concomitant therapy.

When weak inhibitors of CYP3A4 (e.g., diltiazem) or CYP2D6 (e.g., escitalopram) are used concomitantly with ABILIFY MAINTENA, modest increases in plasma aripiprazole concentrations may be expected.

Carbamazepine and other CYP3A4 Inducers

After oral administration of aripiprazole to healthy subjects, following concomitant administration of carbamazepine, an inducer of CYP3A4, the geometric means of Cmax and AUC for aripiprazole were 68% and 73% lower, respectively, compared to when oral aripiprazole (30 mg) was administered alone. Similarly, for dehydro-aripiprazole the geometric means of Cmax and AUC after carbamazepine co-administration were 69% and 71% lower, respectively, than those following treatment with oral aripiprazole alone. Concomitant administration of ABILIFY MAINTENA and other inducers of CYP3A4 (such as rifampicin, rifabutin,
phenytoin, phenobarbital, primidone, efavirenz, nevirapine and St. John's Wort) may be expected to have similar effects. Avoid the concomitant use of CYP3A4 inducers with ABILIFY MAINTENA for more than 14 days because the blood levels of aripiprazole are decreased and may be below the effective levels (see DOSAGE AND ADMINISTRATION Section Table 7 for dose adjustments).

**Potential for aripiprazole to Affect Other Drugs**
In clinical studies, oral doses of 10-30 mg/day had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), 2C9 (warfarin), 2C19 (omeprazole), and 3A4 (dextromethorphan). Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism *in vitro*. Thus, ABILIFY MAINTENA is unlikely to cause clinically important medicinal product interactions mediated by these enzymes. No dosage adjustment of dextromethorphan, warfarin, omeprazole, escitalopram, or venlafaxine is required when co-administered with ABILIFY MAINTENA.

**Drug-Food Interactions**
Interactions with food have not been established.

**Drug-Herb Interactions**
Interactions with herbal products have not been established.

**Drug-Laboratory Interactions**
Interactions with laboratory tests have not been established.

**Drug-Lifestyle Interactions**

*Alcohol/CNS Drugs*
Given the primary CNS effects of aripiprazole, as with most psychoactive medications, combination use of aripiprazole with alcohol or other CNS drugs with overlapping undesirable effects such as sedation, should be avoided.

**DOSAGE AND ADMINISTRATION**

**Dosing Considerations**

*Elderly population*
The safety and efficacy of ABILIFY MAINTENA in patients 65 years of age or older has not been established. No dosage adjustment of ABILIFY MAINTENA is recommended for elderly patients; however, owing to the greater sensitivity of this population, a lower starting dose should be considered when clinical factors warrant.

ABILIFY MAINTENA is not indicated in elderly patients with dementia (see WARNINGS AND PRECAUTIONS - Serious Warnings and Precautions).

*Renal impairment*
No dosage adjustment of ABILIFY MAINTENA is required for patients with renal impairment.

*Hepatic impairment*
No dosage adjustment of ABILIFY MAINTENA is required for patients with mild or moderate hepatic impairment. In patients with severe hepatic impairment, the data available are insufficient to establish recommendations. In these patients dosing should be managed cautiously; use of oral aripiprazole should be considered.
Other special populations

No dosage adjustment of ABILIFY MAINTENA is recommended based on gender, race, or smoking status.

Dose adjustments due to interactions

Dosage adjustments are recommended in patients taking concomitant strong CYP3A4 inhibitors or strong CYP2D6 inhibitors for more than 14 days. If the CYP3A4 inhibitor or CYP2D6 inhibitor is withdrawn, the ABILIFY MAINTENA dosage may need to be increased to the previous dose. Refer to Table 7.

Avoid the concomitant use of CYP3A4 inducers with ABILIFY MAINTENA for more than 14 days because the blood levels of aripiprazole are decreased and may be below the effective levels. Refer to Table 7.

Table 7 Dose Adjustments of ABILIFY MAINTENA in patients who are known CYP2D6 poor metabolizers and patients taking concomitant strong CYP2D6 inhibitors, strong CYP3A4 inhibitors, and/or CYP3A4 inducers for more than 14 days

<table>
<thead>
<tr>
<th>Known CYP2D6 Poor Metabolizers</th>
<th>Adjusted Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Known CYP2D6 Poor Metabolizers</td>
<td>300 mg</td>
</tr>
<tr>
<td>Known CYP2D6 Poor Metabolizers taking strong concomitant CYP3A4 inhibitors</td>
<td>200 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patients Taking 400 mg of ABILIFY MAINTENA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong CYP2D6 or Strong CYP3A4 inhibitors</td>
</tr>
<tr>
<td>Strong CYP2D6 and Strong CYP3A4 inhibitors</td>
</tr>
<tr>
<td>CYP3A4 inducers</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patients Taking 300 mg of ABILIFY MAINTENA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong CYP2D6 or Strong CYP3A4 inhibitors</td>
</tr>
<tr>
<td>Strong CYP2D6 and Strong CYP3A4 inhibitors</td>
</tr>
<tr>
<td>CYP3A4 inducers</td>
</tr>
</tbody>
</table>

Recommended Dose and Dosage Adjustment

ABILIFY MAINTENA is only to be administered by intramuscular injection in the gluteal or deltoid muscle by a Healthcare Professional.

For patients who have never taken aripiprazole, establish tolerability with oral aripiprazole prior to initiating treatment with ABILIFY MAINTENA.

Schizophrenia and Bipolar Disorder

The recommended starting and maintenance dose of ABILIFY MAINTENA is 400 mg. Titration of the dose of ABILIFY MAINTENA is not required. ABILIFY MAINTENA should be administered by a Healthcare Professional once monthly as a single injection (no sooner than 26 days after the previous injection). After the first ABILIFY MAINTENA injection, treatment should be continued with 10 mg to 20 mg oral aripiprazole for 14 consecutive days to maintain therapeutic antipsychotic concentrations during initiation of therapy.

If there are adverse reactions with the 400 mg dosage, reduction of the dose to 300 mg once monthly should be considered.

If ABILIFY MAINTENA is discontinued, its prolonged release characteristics must be considered.
Switching from oral antipsychotics
When switching from oral antipsychotics, patients should continue their current oral antipsychotic for 14 days following the first dose of ABILIFY MAINTENA to maintain therapeutic plasma concentrations during the initiation of ABILIFY MAINTENA. ABILIFY MAINTENA should then be administered monthly as described above. In an open-label study in patients taking oral antipsychotics other than aripiprazole, 34 patients (n=60) followed the recommendation to continue dosing for 14 days. These patients had similar tolerability and PK profiles relative to patients taking oral aripiprazole. 25

Missed Doses

<table>
<thead>
<tr>
<th>Missed doses</th>
<th>If 2nd or 3rd dose is missed and time since last injection is:</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&gt;4 weeks and &lt; 5 weeks</td>
<td>Administer the injection as soon as possible and then resume monthly injection schedule.</td>
</tr>
<tr>
<td></td>
<td>&gt;5 weeks</td>
<td>Restart concomitant oral aripiprazole for 14 days with next administered injection and then resume monthly injection schedule.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>If 4th or subsequent doses are missed and time since last injection is:</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;4 weeks and &lt;6 weeks</td>
<td>Administer the injection as soon as possible and then resume monthly injection schedule.</td>
</tr>
<tr>
<td>&gt;6 weeks</td>
<td>Restart concomitant oral aripiprazole for 14 days with next administered injection and then resume monthly injection schedule.</td>
</tr>
</tbody>
</table>

Administration

ABILIFY MAINTENA comes in two types of kits. See instructions for reconstitution/injection/disposal procedures for 1) Pre-filled Dual Chamber Syringe available in 300 mg or 400 mg strength syringes, and 2) Single-use vials available in 300 mg or 400 mg strength vials.

Dual Chamber Syringe

For deep intramuscular deltoid or gluteal injection: do not administer intravenously or subcutaneously.

Inject immediately after reconstitution. ABILIFY MAINTENA should be administered by a Healthcare Professional once monthly as a single injection.

Any unused product or waste material should be disposed of in accordance with local requirements.

Reconstitution:

Step 1: Preparation Prior to Reconstitution of the Lyophilised ABILIFY MAINTENA Powder

Lay out and confirm that components listed below are provided in the kit:

- One ABILIFY MAINTENA (aripiprazole for prolonged release injectable suspension) pre-filled dual chamber syringe (400 mg or 300 mg as appropriate) containing lyophilized powder and Sterile Water for Injection
- One 22 gauge, 1.5-inch (38 mm) hypodermic needle with needle protection device
- One 21 gauge, 2-inch (51 mm) hypodermic needle with needle protection device
- One 23 gauge, 1-inch (25 mm) hypodermic needle with needle protection device
Step 2: Reconstitution of the Lyophilised Powder in Pre-filled Dual Chamber Syringe

Reconstitute at room temperature.

(a) Push plunger rod slightly to engage threads. And then, rotate plunger rod until the rod stops rotating to release diluent. After plunger rod is at complete stop, middle stopper will be at the indicator line (See Figure 1).

Figure 1

(b) Vertically shake the syringe vigorously for 20 seconds until drug is uniformly milky-white (See Figure 2).

Figure 2

(c) Visually inspect the syringe for particulate matter and discoloration prior to administration. The reconstituted ABILIFY MAINTENA suspension should appear to be a uniform, homogeneous suspension that is opaque and milky-white in color.

Step 3: Injection Procedure

Use appropriate aseptic techniques throughout injection procedure. Do not administer intravenously or subcutaneously.

(a) Twist and pull off Over-cap and Tip-cap (See Figure 3).
(b) Select appropriate needle.

For deltoid administration:
- 23 gauge, 1-inch (25 mm) hypodermic needle with needle protection device for non-obese patients.
- 22 gauge, 1.5-inch (38 mm) hypodermic needle with needle protection device for obese patients.

For gluteal administration:
- 22 gauge, 1.5-inch (38 mm) hypodermic needle with needle protection device for non-obese patients
- 21 gauge, 2-inch (51 mm) hypodermic needle with needle protection device for obese patients

(c) While holding the needle cap, ensure the needle is firmly seated on the safety device with a push. Twist clockwise until SNUGLY fitted (See Figure 4).

(d) Then PULL needle-cap straight up (see Figure 5).

(e) Hold syringe UPRIGHT and ADVANCE PLUNGER ROD SLOWLY TO EXPEL THE AIR. Expel air until suspension fills needle base. If it’s not possible to advance plunger rod to expel the air, check that plunger rod is rotated to a complete stop (See Figure 6).
(f) Inject slowly into the deltoid or gluteal muscle. Do not massage the injection site. Do not administer intravenously or subcutaneously.

**Step 4: Disposal Procedure**

(a) Engage the needle safety device as described in Step 2 (d) of Reconstitution of Lyophilized Powder in Vial and safely discard all kit components (See Figure 7). ABILIFY MAINTENA pre-filled dual chamber syringe is for single-use only.

(b) Rotate sites of injections between the two deltoid or gluteal muscles.

**Vial**

*For deep intramuscular deltoid or gluteal injection: do not administer intravenously or subcutaneously.*

Inject immediately after reconstitution. ABILIFY MAINTENA should be administered by a Healthcare Professional once monthly as a single injection.

Any unused product or waste material should be disposed of in accordance with local requirements.

**Reconstitution:**

**Step 1: Preparation Prior to Reconstitution of the Lyophilised ABILIFY MAINTENA Powder.**

(a) Lay out and confirm that components listed below are provided:

- Vial of ABILIFY MAINTENA (aripiprazole for prolonged release injectable suspension)
- 2.0-mL vial of solvent (sterile water for injection)
- One 3-mL Luer lock syringe with pre-attached 21g x 1.5-inch (38 mm) hypodermic needle with needle protection device
- One 3-mL disposable syringe with Luer lock tip
- One vial adapter
- One 22-gauge, 1.5-inch (38 mm) hypodermic needle with needle protection device
- One 21-gauge, 2-inch (51 mm) hypodermic needle with needle protection device
• One 23-gauge, 1-inch (25 mm) hypodermic needle with needle protection device

(b) ABILIFY MAINTENA should be suspended using the Sterile Water for Injection supplied in the carton.

(c) The Sterile Water for Injection and ABILIFY MAINTENA vials are for single-use only.

(d) Use appropriate aseptic techniques throughout reconstitution and reconstitute at room temperature.

(e) Select the amount of Sterile Water for Injection needed for reconstitution.

<table>
<thead>
<tr>
<th>400 mg Vial</th>
<th>300 mg Vial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose</td>
<td>Sterile Water for Injection</td>
</tr>
<tr>
<td>400 mg</td>
<td>1.9 mL</td>
</tr>
<tr>
<td>300 mg</td>
<td>1.5 mL</td>
</tr>
</tbody>
</table>

It is important to note that there is more Sterile Water for Injection in the vial than is needed to reconstitute ABILIFY MAINTENA (aripiprazole for prolonged release injectable suspension).

**Step 2: Reconstitution of the Lyophilised Powder**

(a) Remove the cap of the vial of Sterile Water for Injection and remove the cap of the vial containing ABILIFY MAINTENA lyophilised powder and wipe the tops with a sterile alcohol swab.

(b) Using the 3 mL syringe with pre-attached hypodermic safety needle, withdraw the pre-determined Sterile Water for Injection volume from the vial of Sterile Water for Injection into the syringe (see Figure 8). A small amount of residual Sterile Water for Injection will remain in the vial following withdrawal.

![Figure 8](image)

(c) Slowly inject the Sterile Water for Injection into the vial containing the ABILIFY MAINTENA lyophilised powder (see Figure 9).

![Figure 9](image)
(d) Withdraw air to equalise the pressure in the vial by pulling back slightly on the plunger. Subsequently, remove the needle from the vial. Engage the needle safety device by using the one-handed technique (see Figure 10). Gently press the sheath against a flat surface until the needle is firmly engaged in the needle protection sheath. Visually confirm that the needle is fully engaged into the needle protection sheath, and discard.

![Figure 10](image)

(e) Shake the vial vigorously for 30 seconds until the suspension appears uniform (see Figure 11).

![Figure 11](image)

(f) Visually inspect the reconstituted suspension for particulate matter and discolouration prior to administration. The reconstituted ABILIFY MAINTENA is a uniform, homogeneous suspension that is opaque and milky-white in colour.

(g) If the injection is not performed immediately after reconstitution, keep the vial below 25°C for up to four hours and shake the vial vigorously for at least 60 seconds to re-suspend prior to injection.

(h) Do not store the reconstituted suspension in the syringe.

**Step 3: Preparation Prior to Injection**

(a) Use appropriate aseptic techniques throughout injection of the reconstituted ABILIFY MAINTENA suspension.

(b) Remove the cover from the vial adapter package (see Figure 12). Do not remove the vial adapter from the package.

![Figure 12](image)
(c) Using the vial adapter package to handle the vial adapter, attach the prepackaged Luer lock syringe to the vial adapter (see Figure 13).

![Figure 13]

(d) Use the Luer lock syringe to remove the vial adapter from the package and discard the vial adapter package (see Figure 14). Do not touch the spike tip of the adapter at any time.

![Figure 14]

(e) Determine the recommended volume for injection.

<table>
<thead>
<tr>
<th>Dose</th>
<th>Volume to Inject</th>
<th>Dose</th>
<th>Volume to Inject</th>
</tr>
</thead>
<tbody>
<tr>
<td>400 mg</td>
<td>2 mL</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>300 mg</td>
<td>1.5 mL</td>
<td>300 mg</td>
<td>1.5 mL</td>
</tr>
<tr>
<td>200 mg</td>
<td>1 mL</td>
<td>200 mg</td>
<td>1 mL</td>
</tr>
<tr>
<td>160 mg</td>
<td>0.8 mL</td>
<td>160 mg</td>
<td>0.8 mL</td>
</tr>
</tbody>
</table>

(f) Wipe the top of the vial of the reconstituted ABILIFY MAINTENA suspension with a sterile alcohol swab.

(g) Place and hold the vial of the reconstituted ABILIFY MAINTENA suspension on a hard surface. Attach the adapter-syringe assembly to the vial by holding the outside of the adapter and pushing the adapter’s spike firmly through the rubber stopper, until the adapter snaps in place (see Figure 15).
(h) Slowly withdraw the recommended volume from the vial into the Luer lock syringe to allow for injection (see Figure 16). A small amount of excess product will remain in the vial.

Figure 15

Figure 16

Step 4: Injection Procedure

(a) Detach the Luer lock syringe containing the recommended volume of reconstituted ABILIFY MAINTENA suspension from the vial.

(b) Select the appropriate hypodermic needle and attach the needle to the Luer lock syringe containing the suspension for injection. While holding the needle cap, ensure the needle is firmly seated on the safety device with a push and clockwise twist until snugly fitted and then pull the needle cap straight away from the needle (see Figure 17).

For deltoid administration:
- 23 gauge, 1-inch (25 mm) hypodermic needle with needle protection device for non-obese patients.
- 22 gauge, 1.5-inch (38 mm) hypodermic needle with needle protection device for obese patients.

For gluteal administration:
- 22 gauge, 1.5-inch (38 mm) hypodermic needle with needle protection device for non-obese patients.
- 21 gauge, 2-inch (51 mm) hypodermic needle with needle protection device for obese patients.
(c) Slowly inject the recommended volume as a single intramuscular injection into the deltoid or gluteal muscle. Do not massage the injection site. Do not administer intravenously or subcutaneously.

**Step 5: Procedures After Injection**

(a) Engage the needle safety device as described in Step 2 (d). Dispose of the vials, adapter, needles, and syringe appropriately after injection. The Sterile Water for Injection and ABILIFY MAINTENA vials are for single-use only.

(b) Rotate sites of injections between the two deltoid or gluteal muscles.

**OVERDOSAGE**

For management of a suspected drug overdose, contact your regional Poison Control Centre.

No cases of overdose were reported in pre-marketing studies with ABILIFY MAINTENA. Because ABILIFY MAINTENA is to be administered by Healthcare Professionals; the potential for overdosage by patients is low.

While overdose is less likely with parenteral than oral medicinal products, reference information for oral aripiprazole overdose is presented below.

**Symptoms**

In post-marketing experience with oral aripiprazole, there is a single case of death that was possibly associated with accidental or intentional acute overdosage of aripiprazole alone. The patient ingested 900 mg of aripiprazole, was hospitalized in the intensive care unit for 10 to 14 days and died. The patient’s medical history included excessive alcohol use, although it is unclear whether alcohol was present at the time of overdosage. In the patient taking the largest confirmed amount of aripiprazole, 1680 mg, the only symptoms reported were vomiting, fatigue, and dizziness. Other potentially medically important signs and symptoms that have been observed during overdose included blood pressure increased, lethargy, somnolence, tachycardia, nausea, vomiting and diarrhea. In the patients who were evaluated in hospital settings, there were no reported observations indicating clinically important adverse change in vital signs, laboratory assessments, or electrocardiogram.

In addition, a report of non-fatal accidental overdose with aripiprazole alone (up to 195 mg) in a 2.5 year old child has been received. Vomiting, somnolence, lethargy, transient loss of consciousness and CNS depression were reported for this patient. Potentially medically serious signs and symptoms reported in cases of accidental overdose with aripiprazole alone (up to 195 mg) in children included somnolence, transient loss of consciousness and extrapyramidal symptoms.
Common adverse reactions (reported in at least 5% of all overdose cases) reported with oral aripiprazole overdose (alone or in combination with other substances) include vomiting, somnolence, and tremor. Other clinically important signs and symptoms observed in one or more patients with aripiprazole overdoses (alone or with other substances) include acidosis, aggression, aspartate aminotransferase increased, atrial fibrillation, bradycardia, coma, confusional state, convulsion, blood creatine phosphokinase increased, depressed level of consciousness, hypertension, hypokalemia, hypotension, lethargy, loss of consciousness, QRS complex prolonged, QT prolonged, pneumonia aspiration, respiratory arrest, status epilepticus, and tachycardia.

Management
Management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. The possibility of multiple medicinal product involvement should be considered. Therefore cardiovascular monitoring should be started immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias. Following any confirmed or suspected overdose with aripiprazole, close medical supervision and monitoring should continue until the patient recovers.

Activated charcoal (50 g), administered one hour after ingesting oral aripiprazole, decreased aripiprazole C_max by about 41% and AUC by about 51%, suggesting that charcoal may be effective in the treatment of overdose.

Although there is no information on the effect of haemodialysis in treating an overdose with aripiprazole, haemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action
The mechanism of action of aripiprazole, as with other drugs having efficacy in schizophrenia or bipolar I disorder is unknown. However, it has been proposed that the efficacy of aripiprazole may be mediated through a combination of partial agonist activity at D_2 and 5-HT_{1A} receptors and antagonist activity at 5-HT_{2A} receptors; however, the clinical relevance of these interactions has not been established. Actions at receptors other than D_2, 5-HT_{1A}, and 5-HT_{2A} may explain some of the other adverse reactions of aripiprazole (e.g., the orthostatic hypotension observed with aripiprazole may be explained by its antagonist activity at adrenergic alpha1 receptors). The clinical relevance of these receptor interactions with aripiprazole is unknown.

Pharmacodynamics
Aripiprazole exhibits high affinity for dopamine D_2 and D_3 and serotonin 5-HT_{1A} and 5-HT_{2A} receptors (Ki values of 0.34 nM, 0.8 nM, 1.7 nM, and 3.4 nM, respectively) and has moderate affinity for dopamine D_4, serotonin 5-HT_{2C} and 5-HT_7, α_1-adrenergic, histamine H_1 receptors (Ki values of 44 nM, 15 nM, 39 nM, 57 nM and 61 nM, respectively), and the serotonin reuptake site (Ki=98 nM). Aripiprazole also displays 5-HT_{1A} partial agonist and 5-HT_{2A} antagonist activity in nonclinical studies. 4,5

Pharmacokinetics
ABILIFY MAINTENA’s activity is presumably primarily due to the parent drug, aripiprazole, and to a lesser extent, to its major metabolite, dehydro-aripiprazole, which has been shown to have affinities for D_2 receptors similar to the parent drug and represents approximately 29% of the parent drug exposure in plasma at steady state.
Absorption: Aripiprazole absorption into the systemic circulation is slow and prolonged following ABILIFY MAINTENA administration due to low solubility of aripiprazole particles. Following a single dose administration of ABILIFY MAINTENA in the deltoid and gluteal muscle, the extent of absorption (AUC) was similar for both injection sites, but the rate of absorption (\(C_{\text{max}}\)) was higher following administration to the deltoid. Following multiple intramuscular doses, the plasma concentrations of aripiprazole gradually rise to a maximum plasma concentration at a median \(T_{\text{max}}\) of 7 days for the gluteal muscle and 4 days for the deltoid muscle. Approximate dose-proportional increases in aripiprazole and dehydro-aripiprazole concentrations and AUC parameters are observed after monthly ABILIFY MAINTENA injections of 400 mg and 300 mg and steady state aripiprazole plasma concentrations for the typical subject were attained by the fourth monthly injection for both sites of administration. When oral aripiprazole is not administered prior to initiation of ABILIFY MAINTENA, the predicted median aripiprazole concentration reaches the lower threshold of therapeutic window by Day 3 after ABILIFY MAINTENA administration, however, the median aripiprazole concentration-time profile remains very near the lower threshold over the full dosing interval. In contrast, if oral aripiprazole is administered prior to initiation of ABILIFY MAINTENA or at the same time of its initiation, median aripiprazole concentration is maintained above or reaches the lower threshold of therapeutic window by Day 1-2, respectively and is maintained above threshold of therapeutic window for the first 21 days after the first administration of ABILIFY MAINTENA. Of note, regardless of administration of oral aripiprazole prior to or after the first ABILIFY MAINTENA injection, the predicted median aripiprazole concentrations during days 21-28 from the first ABILIFY MAINTENA administration are comparable.

Distribution: The steady-state volume of distribution of aripiprazole following intravenous administration is high (404 L or 4.9 L/kg), indicating extensive extravascular distribution. At therapeutic concentrations, aripiprazole and dehydro-aripiprazole are greater than 99% bound to serum proteins, binding primarily to albumin.

Metabolism: Aripiprazole is extensively metabolised by the liver primarily by three biotransformation pathways: dehydrogenation, hydroxylation, and N-dealkylation. Based on in vitro studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalysed by CYP3A4. Aripiprazole is the predominant medicinal product moiety in systemic circulation. After multiple dose administration of ABILIFY MAINTENA, dehydro-aripiprazole, the active metabolite, represents about 29% of aripiprazole AUC in plasma.

CYP2D6 Poor Metabolizers
Approximately 8% of Caucasians lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are extensive metabolizers (EM). PMs have about an 80% increase in aripiprazole exposure and about a 30% decrease in exposure to the active metabolite compared to EMs, resulting in about a 60% higher exposure to the total active moieties from a given dose of aripiprazole compared to EMs. Co-administration of aripiprazole with known inhibitors of CYP2D6, like quinidine in EMs, results in a 112% increase in aripiprazole plasma exposure, and dose adjustment is needed (see DRUG INTERACTIONS). The mean elimination half-life for aripiprazole is about 75 hours in EMs and 146 hours in PMs. Aripiprazole does not inhibit or induce the CYP2D6 pathway (see Dosage and Administration; Dose adjustments due to interactions).

Excretion: After multiple dose administration of 300 mg or 400 mg of ABILIFY MAINTENA, the mean aripiprazole terminal elimination half-life is 29.9-46.5 days.
Special Populations and Conditions

Geriatrics
In formal single-dose pharmacokinetic studies (with oral aripiprazole given in a single dose of 15 mg), aripiprazole clearance was 20% lower in elderly (≥65 years) subjects compared to younger adult subjects (18 to 64 years). There was no detectable age effect, however, in the population pharmacokinetic analysis in patients with schizophrenia. Also, the pharmacokinetics of aripiprazole after multiple doses in elderly patients appeared similar to that observed in young, healthy subjects (see WARNINGS AND PRECAUTIONS - Serious Warnings and Precautions Box and DOSAGE AND ADMINISTRATION - Geriatrics).

Gender
C<sub>max</sub> and AUC of aripiprazole and its active metabolite, dehydro-aripiprazole, are 30 to 40% higher in women than in men, and correspondingly, the apparent oral clearance of aripiprazole is lower in women. These differences, however, are largely explained by differences in body weight (25%) between men and women. No dosage adjustment is recommended based on gender.

Race
Although no specific pharmacokinetic study was conducted to investigate the effects of race on the disposition of aripiprazole, population pharmacokinetic evaluation of ABILIFY MAINTENA showed no evidence of race-related differences on the pharmacokinetics of aripiprazole.

Hepatic Insufficiency
In a single-dose trial (15 mg of oral aripiprazole) in subjects with varying degrees of liver cirrhosis (Child-Pugh Classes A, B, and C), the AUC of aripiprazole, compared to healthy subjects, increased 31% in mild hepatic impairment, increased 8% in moderate hepatic impairment, and decreased 20% in severe hepatic impairment, but the study included only 3 patients with Class C liver cirrhosis, which is insufficient to draw conclusions on their metabolic capacity.

Renal Insufficiency
In patients with severe renal impairment (creatinine clearance <30 mL/min), C<sub>max</sub> of aripiprazole (given in a single oral dose of 15 mg) and dehydro-aripiprazole increased by 36% and 53%, respectively, but AUC was 15% lower for aripiprazole and 7% higher for dehydroaripiprazole. Renal excretion of both unchanged aripiprazole and dehydro-aripiprazole is less than 1% of the dose. No dosage adjustment is required in subjects with renal impairment.

Smoking
Based on studies utilizing human liver enzymes in vitro, aripiprazole is not a substrate for CYP1A2 and also does not undergo direct glucuronidation. Smoking should, therefore, not have an effect on the pharmacokinetics of aripiprazole. Population pharmacokinetic evaluation of oral aripiprazole has revealed no evidence of clinically relevant effects from smoking on the pharmacokinetics of aripiprazole.
STORAGE AND STABILITY

**Pre-filled dual chamber syringe:**
Store between 15 and 30 °C. Do not freeze. Protect the syringe from light by storing in the original package until time of use.

**Vial:**
Store between 15 and 30 °C.
For storage conditions after reconstitution of the medicinal product, see **DOSAGE AND ADMINISTRATION**.

DOSAGE FORMS, COMPOSITION AND PACKAGING

**Dual chamber syringe:**
ABILIFY MAINTENA pre-filled dual chamber syringe in single-use syringes is available in 300 mg or 400 mg strength syringes. The pre-filled dual chamber syringe consists of a front chamber that contains the lyophilized powder of aripiprazole monohydrate and a rear chamber that contains sterile water for injection. One carton contains one single-use pre-filled dual chamber syringe containing powder and solvent, one 1.5-inch (38 mm) 22 gauge sterile safety needle, one 2-inch (51 mm) 21 gauge sterile safety needle and one 1-inch (25 mm) 23 gauge hypodermic safety needle.

ABILIFY MAINTENA contains the following excipients; carboxymethyl cellulose sodium, mannitol, sodium phosphate monobasic monohydrate, and sodium hydroxide.

**Vial:**
ABILIFY MAINTENA is available in two dosage strengths, 300 mg and 400 mg and is provided as a lyophilized powder for reconstitution. One carton contains one vial of powder, one vial of solvent (sterile water for injection), one 3 mL sterile syringe with a 21 gauge needle for reconstitution, one sterile syringe without needle, one 1.5-inch (38 mm) 22 gauge sterile safety needle, one 2-inch (51 mm) 21 gauge sterile safety needle, one 1-inch (25 mm) 23 gauge hypodermic safety needle with needle protection device and one vial adapter.

ABILIFY MAINTENA contains the following excipients; carboxymethyl cellulose sodium, mannitol, sodium phosphate monobasic monohydrate, and sodium hydroxide.

ABILIFY MAINTENA is presented in a Type-I glass vial stoppered with a Teflon laminated rubber stopper and sealed with a flip-off aluminium cap.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: aripiprazole monohydrate

Chemical name: 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4 dihydrocarbostyril as monohydrate

Molecular formula: C_{23}H_{27}Cl_{2}N_{3}O_{2}H_{2}O

Molecular mass: 466.40 g/mol

Structural formula:

```
Cl Cl
\[N\ \ \ N-CH_{2}CH_{2}CH_{2}CH_{2}O\] \cdot H_{2}O
```

Physicochemical properties: Aripiprazole monohydrate is a white to off white crystalline powder. Aripiprazole monohydrate is practically insoluble in water. The pKa was determined to be 7.6 (in 20% ethanol solution).

CLINICAL TRIALS

The efficacy of ABILIFY MAINTENA in achieving and maintaining symptomatic control and delaying relapse in schizophrenia was established in three randomized, double-blind trials. In addition, the efficacy of ABILIFY MAINTENA in the treatment of patients with schizophrenia was established, in part, on the basis of efficacy data from trials with the oral formulation of aripiprazole.

The efficacy of ABILIFY MAINTENA as maintenance treatment in adults with bipolar I disorder was demonstrated in a 52-week multicenter, randomized, double-blind, placebo-controlled trial of patients with bipolar I disorder who were currently experiencing a manic episode at trial entry. An additional 52-week open label trial was conducted to primarily assess the safety of ABILIFY MAINTENA. In addition, the efficacy of ABILIFY MAINTENA in the treatment of patients with bipolar I disorder was established, in part, on the basis of efficacy data from trials with the oral formulation of aripiprazole.

Clinical Efficacy in the Acute Phase of Schizophrenia

The efficacy of ABILIFY MAINTENA in adult patients in the acute phase of schizophrenia was established in one short-term (12-week), randomized, double-blind, placebo controlled trial of acutely relapsed adult patients. In this trial, the primary measure used for assessing psychiatric signs and symptoms was the Positive and Negative Syndrome Scale (PANSS). The primary endpoint was the change from baseline to week 10 in
The inclusion criteria for this short term trial included adult inpatients who met DSM-IV-TR criteria for schizophrenia. In addition, all patients entering the trial must have experienced an acute psychotic episode as defined by both PANSS Total Score ≥ 80 and a PANSS score of > 4 on each of four specific psychotic symptoms (conceptual disorganization, hallucinatory behavior, suspiciousness/persecution, unusual thought content) at screening and baseline. Patients had a mean PANSS total score of 103 (range 82 to 144) and a CGI-S score of 5.0 (markedly ill) at entry.

In this 12-week study (n=339) comparing ABILIFY MAINTENA (n=167) to placebo (n=172), patients were administered 400 mg ABILIFY MAINTENA or placebo on days 0, 28, and 56. The dose could be adjusted down and up within the range of 400 to 300 mg on a one time basis. (For the first two weeks of the study, subjects randomized to ABILIFY MAINTENA also received concomitant oral ABILIFY, 10 to 20 mg/day). ABILIFY MAINTENA was superior to placebo in improving the PANSS total score with early onset and sustained efficacy (week 10 scores of -26.8 vs. -11.7 respectively) with a statistical difference at each measured time point, p=<0.0005 at week 1 and p=<0.0001 for all other time points until study completion. The adjusted mean change in PANSS total score over time (Mixed Model of Repeated Measure MMRM) is demonstrated in Figure 1.

Figure 1: Adjusted Mean Change from Baseline in PANSS Total Score – MMRM

ABILIFY MAINTENA also showed improvement in CGI-S score mean changes from baseline that were statistically significant at all post-baseline timepoints (week 10 scores of -1.4 vs. -0.6 at week 10, ABILIFY MAINTENA vs. placebo, respectively).
Clinical Efficacy in the Maintenance Phase of Schizophrenia

The first trial, Trial 1, was a 38-week, randomized, double-blind, active-controlled trial designed to establish the efficacy, safety, and tolerability of ABILIFY MAINTENA 400 mg/300 mg administered as monthly injections compared to once daily oral aripiprazole tablets 10-30 mg as maintenance treatment in adult patients with schizophrenia as defined by DSM-IV-TR criteria and a history of the illness for at least 3 years prior to screening and with a history of relapse and/or exacerbation of symptoms when they were not receiving antipsychotic treatment. 12

This trial consisted of a screening phase and 3 treatment phases:

- A conversion Phase (4 to 6 weeks) for all subjects to achieve a monotherapy target starting dose of 10 or 15 mg oral aripiprazole. A total of 709 patients entered this phase.

- An oral Stabilization Phase (a minimum of 8 weeks and a maximum of 28 weeks in duration) during which subjects were stabilized on an oral dose of aripiprazole ranging from 10 mg to 30 mg daily. Stabilization was defined as having all of the following for eight consecutive weeks: an outpatient status, PANSS total score ≤80, CGI-S ≤4 (moderately ill), and CGI-SS score ≤2 (mildly suicidal) on Part 1 and ≤5 (minimally worsened) on Part 2; and a score of ≤4 on each of the following PANSS items: conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content. A total of 842 patients entered this phase. The majority of subjects who were enrolled in the Oral Stabilization Phase were male (518/842, 61.5%), Caucasian (489/842, 58.1%). The mean age was 40.8 years (range, 18 to 60 years). The mean baseline PANSS total score was 63.8 (range, 30 to 110). The mean baseline CGI-S severity and CGI-SS severity scores were 3.4 and 1.0, respectively.

- Double-blind, Active-controlled Phase.

Six-hundred and sixty two patients eligible for the 38-week Double-Blind, Active-Controlled Phase were randomly assigned in a 2:2:1 ratio to double-blind treatment to one of 3 treatment groups: 1) ABILIFY MAINTENA 400 mg/300 mg, 2) the stabilization dose of oral aripiprazole 10-30 mg, or 3) aripiprazole IM depot 50 mg/25 mg. The aripiprazole IM depot 50 mg/25 mg dose was included as a low dose aripiprazole group to test assay sensitivity for the non-inferiority design. The overall demographic characteristics for randomized subjects were similar to those seen in the previous phases; most subjects randomized were male (406/662, 61.3%), Caucasian (387/662, 58.5%); the mean age was 41.2 years (range, 18 to 60 years). Baseline disease severity was comparable across the 3 treatment groups. The mean age at first diagnosis of schizophrenia was 28.2, 26.9, and 26.3 years for the ABILIFY MAINTENA 400 mg/300 mg, oral aripiprazole tablets 10-30 mg, and IM depot 50 mg/25 mg groups, respectively. The mean baseline PANSS total score was 58.0, 56.6, and 56.1 for the ABILIFY MAINTENA 400 mg/300 mg, oral aripiprazole tablets 10-30 mg, and IM depot 50 mg/25 mg groups, respectively. The mean baseline CGI-S was 3.1 in both the ABILIFY MAINTENA 400 mg/300 mg and oral aripiprazole tablets 10-30 mg groups, and 3.0 in the IM depot 50 mg/25 mg group. Mean baseline CGI-SS was 1.0 in all 3 treatment groups.

The primary efficacy endpoint, was the estimated proportion of patients experiencing impending relapse by end of Week 26 of the Double-blind, Active-controlled Phase.

Impending relapse was defined as meeting any or all of the following 4 criteria:
1) Clinical Global Impression of Improvement (CGI-I) of ≥ 5 (minimally worse)
   AND
   • an increase on any of the following individual Positive and Negative Syndrome Scale (PANSS) items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) to a score > 4 with an absolute increase of ≥ 2 on that specific item since randomization OR
The estimated proportion of patients experiencing impending relapse by end of Week 26 for the ABILIFY MAINTENA 400 mg/300 mg group was 7.12%, which was statistically significantly lower than in the aripiprazole IM depot 50 mg/25 mg group (21.80%; \( p = 0.0006 \)). Thus, superiority of ABILIFY MAINTENA 400 mg/300 mg over the aripiprazole IM depot 50 mg/25 mg was established and the validity of the trial design was confirmed. The proportion of subjects who met the stability criteria at endpoint in the Double-blind, Active-controlled Phase was 89.8% (237/264) in the ABILIFY MAINTENA 400 mg/300 mg group compared with 75.2% (97/129) in the aripiprazole IM depot 50 mg/25 mg group.

The Kaplan-Meier curves of the secondary efficacy endpoint time from randomization to impending relapse during the 38-week, double-blind treatment phase for ABILIFY MAINTENA 400 mg/300 mg, oral aripiprazole 10-30mg group, and aripiprazole IM depot 50 mg/25 mg groups are shown in Figure 2. The aripiprazole IM depot 50 mg/25 mg group had a 3.158-fold higher risk of relapse than the ABILIFY MAINTENA 400 mg/300 mg group (95% CI = 1.813, 5.502). As shown below, ABILIFY MAINTENA significantly delayed time to impending relapse.

**Figure 2: Kaplan-Meier Product Limit Plot for Time to Exacerbation of Psychotic Symptoms/Impending Relapse***

![Kaplan-Meier Product Limit Plot](image)

*ARIP IMD = ABILIFY MAINTENA; ORAL ARIP = oral aripiprazole;

The second trial, Trial 2, was a 52-week, randomized-withdrawal, double-blind, placebo-controlled trial conducted in adult patients with a current diagnosis of schizophrenia as defined by DSM-IV-TR criteria and a history of the illness for at least 3 years prior to screening and with a history of relapse and/or exacerbation of
symptoms when they were not receiving antipsychotic treatment. This trial consisted of a screening phase and 4 treatment phases:

- A 4-6 week open-label, oral conversion phase for patients on antipsychotic medications other than aripiprazole. A total of 633 patients entered this phase.

- An open-label, oral aripiprazole stabilization phase (target dose of 10 mg to 30 mg once daily). A total of 710 patients entered this phase. Patients were 18 to 60 years old (mean 40 years) and 60% were male. The mean PANSS total score was 66 (range 33 to 124). The mean CGI-S score was 3.5 (mildly to moderately ill). Prior to the next phase, stabilization was required. Stabilization was defined as having all of the following for four consecutive weeks: an outpatient status, PANSS total score ≤80, CGI-S ≤4 (moderately ill), and CGI-SS score ≤2 (mildly suicidal) on Part 1 and ≤5 (minimally worsened) on Part 2; and a score of ≤4 on each of the following PANSS items: conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content.

- A 12-week uncontrolled, single-blind ABILIFY MAINTENA stabilization phase (treatment with 400 mg of ABILIFY MAINTENA given every 4 weeks in conjunction with oral aripiprazole [10 mg to 20 mg/day] for the first 2 weeks). The dose of ABILIFY MAINTENA may have been decreased to 300 mg due to adverse reactions. A total of 576 patients entered this phase. The mean PANSS total score was 59 (range 30 to 80) and the mean CGI-S score was 3.2 (mildly ill). Prior to the next phase, stabilization was required (see above for the definition of stabilization) for 12 consecutive weeks.

- A double-blind, placebo-controlled randomized-withdrawal phase to observe for relapse (defined as in trial 1). A total of 403 patients were randomized 2:1 to the same dose of ABILIFY MAINTENA they were receiving at the end of the stabilization phase, (400 mg or 300 mg administered once every 4 weeks) or placebo. Patients had a mean PANSS total score of 55 (range 31 to 80) and a CGI-S score of 2.9 (mildly ill) at entry. The dose could be adjusted up and down or down and up within the range of 300 to 400 mg on a one time basis.

The trial design included two pre-specified interim analyses for efficacy in order to minimize continued exposure to placebo and the risk of relapse: the first was to occur after accrual of 50% of the 125 targeted impending relapse events (64 events) and the second was to occur after 75% accrual of the events (94 events). A Data Monitoring Committee (DMC) was responsible for ongoing safety monitoring and evaluation of efficacy from the pre-specified interim analyses. Since the first pre-specified interim analysis showed statistically significant superiority of ABILIFY MAINTENA over IM placebo in time to impending relapse, the study was terminated early. 13

The final efficacy analysis included 403 randomized patients and 80 “exacerbation of psychosis/impending relapse” events. In this analysis, time to impending relapse was significantly delayed with ABILIFY MAINTENA compared with IM placebo (p < 0.0001; log-rank test).

Similar results were observed at the interim analysis, with a significantly longer time to impending relapse with ABILIFY MAINTENA compared with placebo (log-rank test, P<.0001 and significantly lower relapse rates with ABILIFY MAINTENA (9.6% n=22/230) than placebo (36.8%; n=42/114; HR=4.72, 95% CI, 2.81-7.94)

The Kaplan-Meier curves of the time from randomization to impending relapse during the double-blind treatment phase for ABILIFY MAINTENA and placebo groups are shown in Figure 3.
The key secondary efficacy endpoint, proportion of subjects meeting the impending relapse criteria, was significantly lower in the ABILIFY MAINTENA 400 mg/300 mg group (interim analysis: 9.6%; final analysis: 10.0%) than in the placebo group (interim analysis: 36.8%; final analysis: 39.6%).

Clinical Efficacy in Maintenance Treatment of Bipolar I Disorder

The safety and efficacy of ABILIFY MAINTENA as maintenance treatment in adults with bipolar I disorder aged 18 to 65 years was demonstrated in a 52-week multicenter, randomized, double-blind, placebo-controlled trial (Trial 31-08-250) of patients who met DSM-IV-TR criteria for bipolar I disorder and who were currently experiencing a manic episode at trial entry.

This trial consisted of a screening phase and 4 treatment phases:

- An oral conversion phase (4 to 6 weeks) for all subjects to achieve a monotherapy target starting dose of 15 mg/day oral aripiprazole. A total of 466 patients entered this phase.

- An oral stabilization phase (a minimum of 2 weeks and a maximum of 12 weeks in duration) during which subjects were stabilized on an oral dose of aripiprazole ranging from 15 mg to 30 mg daily. Stabilization was defined as having all of the following stability criteria at one biweekly visit in order to proceed to ABILIFY MAINTENA stabilization phase: outpatient status, YMRS total score ≤ 12, MADRS total score ≤ 12, no active suicidality; with active suicidality defined as a score of 4 or more on the MADRS item 10 OR an answer of “yes” on question 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS). A total of 632 patients entered this phase of which 265 patients entered the oral stabilization phase directly.

- ABILIFY MAINTENA Stabilization Phase (a minimum of 8 weeks and a maximum of 28 weeks in duration) during which subjects were stabilized on ABILIFY MAINTENA 400 mg or 300 mg, as dictated by tolerability. Oral dosing with aripiprazole continued for the first 2 weeks following the
injection to maintain therapeutic plasma concentrations. Stabilization was defined as having all of the following for eight consecutive weeks: an outpatient status, YMRS total score \( \leq 12 \), MADRS total score \( \leq 12 \), no active suicidality; with active suicidality defined as a score of 4 or more on the MADRS item 10 OR an answer of “yes” on question 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS). A total of 425 patients entered this phase. The mean baseline YMRS total score was 5.8 (range, 0 to 28). The mean baseline MADRS total score were 3.7 (range, 0 to 28). The mean baseline CGI-BP-S overall score was 2.1 (range, 1 to 5). Patients who demonstrated stability for 8 consecutive weeks were randomized into the double-blind, placebo-controlled treatment phase.

- A randomized, double-blind, placebo-controlled phase (52 weeks). Two hundred sixty six (266) patients eligible for the 52-week double-blind, placebo-controlled phase were randomly assigned in a 1:1 ratio to double-blind treatment with either the last stabilization dose of ABILIFY MAINTENA from the previous phase or placebo. During this phase, a single decrease to ABILIFY MAINTENA 300 mg was permitted for tolerability, as was a single return to the original 400 mg dose if required. The mean baseline YMRS total score was 2.9, and 2.6 for the ABILIFY MAINTENA 400 mg/300 mg and placebo groups, respectively. The mean baseline MADRS total score was 3.0 and 2.4 for the ABILIFY MAINTENA 400 mg/300 mg and placebo groups, respectively. The mean baseline CGI-BP-S score was 1.5 and 1.4 for the ABILIFY MAINTENA 400 mg/300 mg and placebo groups, respectively.

The primary efficacy endpoint of this trial was the time from randomization to recurrence of any mood episode during the double-blind, placebo-controlled phase.

The time to recurrence of any mood episode was significantly longer in subjects randomized to the ABILIFY MAINTENA group compared to placebo-treated subjects. A total of 103 mood events were observed during the double-blind treatment phase: 35 occurred during ABILIFY MAINTENA treatment and 68 occurred during placebo treatment (26.5% vs 51.1%, \( p < 0.0001 \)). The hazard ratio from the Cox proportional hazard model for the ABILIFY MAINTENA to placebo comparison was 0.451 (95% CI = 0.299, 0.678), subjects in the ABILIFY MAINTENA group had less than half the risk of experiencing recurrence of any mood episode compared with subjects in the placebo group. Thus, superiority of ABILIFY MAINTENA over placebo was established. The analysis of the primary efficacy endpoint is shown in the Kaplan-Meier curves below (Figure 4).
Secondary and other efficacy endpoints were generally supportive of the primary efficacy outcome.

ABILIFY MAINTENA as maintenance treatment in adults with bipolar I disorder was assessed in a 52-week multicentre, open-label trial (n=464, Trial 31-08-252). Safety and tolerability were supportive of the results observed in the double-blind, placebo-controlled study.

DETAILED PHARMACOLOGY

Nonclinical pharmacodynamics
Extensive in vitro and in vivo studies demonstrated that aripiprazole is a potent partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at serotonin 5-HT2 receptors. Aripiprazole binds with high affinity to dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, with moderate affinity to dopamine D4, serotonin 5-HT2C and 5-HT7, alpha1- adrenergic and histamine H1 receptors and the serotonin transporter and with low affinity to muscarinic receptors. As a D2 partial agonist, aripiprazole blocks postsynaptic D2 receptors at a dose comparable to that at which it acts as agonist at presynaptic dopamine receptors.19,20,21

Aripiprazole exhibits the properties of an agonist in animal models of dopaminergic hypoactivity and the properties of an antagonist in animal models of dopaminergic hyperactivity. In multiple behavioral models, aripiprazole exhibits an antipsychotic profile and is several-fold less potent than atypical antipsychotics in animal models predictive of extrapyramidal side effect liability.

Cardiorespiratory System
Aripiprazole and OPC-14857 inhibited the hERG/IKr current at 140- and 461-fold multiples of the maximum steady-state plasma free-drug concentration, respectively, and there were no effects on action potential duration (APD) in the rabbit Purkinje fiber assay. OPC-3373 demonstrated no in vitro inhibition of hERG/IKr
current or prolongation of APD at concentrations up to 10 µM. Neither aripiprazole nor the main human metabolites (OPC-14857, OPC-3373) accumulate in rat cardiac tissue following single or repeat (13 days) dosing. Potential cardiovascular effects were also assessed in in vitro and in vivo safety pharmacology (anesthetized dogs) and toxicology studies (39-week treatment in monkeys) in which no significant changes were observed.

**Central and Peripheral Nervous Systems**
In animals, aripiprazole was less potent than chlorpromazine and haloperidol in producing behavioral signs consistent with CNS depression, in inducing catalepsy, and in suppressing spontaneous motor activity and, unlike these comparators, did not cause convulsions. Additionally, it reduced motor coordination and prolonged the duration of hexobarbital-induced hypnosis with a potency comparable to chlorpromazine. In contrast, aripiprazole demonstrated less potential than chlorpromazine or haloperidol to induce muscular relaxation and analgesia.

**Other Systems and Tissues**
*In vitro* and *in vivo* safety pharmacology studies were conducted to assess the potential of aripiprazole to alter gastric secretion, gastrointestinal motility, smooth muscle contractility, and urine volume and electrolyte excretion. These studies indicated that aripiprazole has little potential to cause gastrointestinal or renal side effects or affect smooth muscle contractility.

**Nonclinical Pharmacokinetics**
The absorption, distribution, metabolism and excretion properties of aripiprazole were evaluated in a series of *in vitro* and *in vivo* studies in mice, rats, rabbits, dogs, minipigs, and monkeys. Aripiprazole had only moderate intrinsic membrane permeability *in vitro*, but was well absorbed following oral administration in animals and humans.

Following intravenous administration of aripiprazole, its elimination half-life (1 to 5 hours) was shorter and its plasma clearance (14 to 110 mL/min/kg) was more rapid in animals than in humans (75 hours and 0.7 mL/min/kg, respectively). As in humans, the steady-state volumes of distribution in animals suggest extensive extravascular distribution.

The exposure of mice, rats, and monkeys to aripiprazole after oral dosing was dose-related. In rats, possibly due to saturation of presystemic metabolism and/or clearance, the increase in exposure was greater than the dose increment; however, in mice and monkeys, exposure increased in a generally dose-proportional manner. After repeated daily doses, exposures to aripiprazole and its pharmacologically-active metabolite, dehydro-aripiprazole, were slightly higher in female rats than in male rats; there were no gender-related differences in mice or monkeys. Systemic accumulation of aripiprazole and its metabolites was seen at toxicologically relevant doses after once-daily chronic administration in both rats and monkeys.

In rats, concentrations of unchanged aripiprazole in the brain were up to 5-times higher than plasma concentrations. Following [14C]-aripiprazole administration to pregnant rats, radioactivity in the fetus was low and only a trace amount was detected in the amniotic fluid. After [14C]-aripiprazole administration to lactating rats, milk vs blood concentration ratios were greater than one for up to 24 hours. *In vitro*, aripiprazole bound extensively (99.4 to 99.8%) to proteins in mouse, rat, rabbit, dog, monkey, and human sera.

Parent drug was undetectable in rat and monkey urine, indicating that renal clearance is not an important mechanism of elimination. Aripiprazole was mainly eliminated via metabolic clearance and aripiprazole metabolites were eliminated by both renal and biliary routes in monkeys and predominantly by the biliary route in rats. After oral administration of [14C]- aripiprazole to rats and monkeys, drug-derived radioactivity was recovered primarily in the feces (~90 and 62% of dose, respectively). The metabolism of aripiprazole in rats and monkeys was qualitatively similar to that in humans, though the rate of elimination through
metabolism in humans was slower compared to animals. The metabolism of aripiprazole was primarily by
dehydrogenation, hydroxylation, and N-dealkylation. Formation of the pharmacologically-active dehydro-
aripiprazole was a major route metabolism. This and other Phase 1 metabolites were subject to further
metabolism, including conjugation reactions. In rats, as in humans, unchanged drug was the major drug-
related component in plasma, while in monkeys, aripiprazole accounted for only 13% of the drug-related
material in plasma. All of the major metabolites in human plasma were present in the plasma rats and
monkeys, the principle species used for nonclinical toxicity testing, indicating that these species were
appropriate for safety assessment of aripiprazole and its metabolites.

*In vitro* studies indicated that cytochrome P450 (CYP) isoforms, CYP3A4 and CYP2D6 were responsible
for the dehydrogenation and hydroxylation of aripiprazole, while its N-dealkylation was catalyzed by CYP3A4
only. Clinical studies were conducted to evaluate the potential for drug-drug interactions *in vivo*. While
coadministration of CYP3A4 or CYP2D6 inhibitors decreased the oral clearance of aripiprazole by
approximately 40-50% and coadministration of an inducer of CYP3A4 increased the oral clearance of
aripiprazole, these changes were not regarded as clinically meaningful. *In vitro* studies also indicated that
neither aripiprazole nor its dehydro metabolite should meaningfully inhibit the *in vivo* activity of CYP
isozymes at clinically relevant concentrations. This was confirmed in clinical studies in which no clinically-
meaningful effect of aripiprazole on the clearance of substrates for CYP3A4, CYP2D6, CYP2C9, and
CYP2C19 was found.

**TOXICOLOGY**

**Intramuscular Aripiprazole**
The toxicological profile for aripiprazole administered to experimental animals by intramuscular injection is
generally similar to that seen following oral administration at comparable plasma levels of the drug. With
intramuscular injection, however, injection-site tissue reactions are observed that consist of localised
inflammation, swelling, scabbing and foreign-body reactions to deposited drug. These effects gradually
resolved with discontinuation of dosing.

**Acute Toxicity**
The acute oral toxicity of aripiprazole was determined in rats and monkeys. The estimated median lethal oral
dose in male and female rats was 953 and 705 mg/kg, respectively, and in monkeys was greater than 2000
mg/kg for both sexes. Clinical signs consistent with pharmacologically mediated central nervous (CNS)
depression and extrapyramidal side effects were noted in both species. In rats, clinical signs included
decreased spontaneous motor activity, crouching, prone position, ataxia, tremors, convulsions, straub tail,
catalepsy, ptosis, and coldness to touch. In monkeys, principal drug-related effects included impaired motor
activity, hyporeactivity to external stimuli, tremors, catalepsy, closed eyes, crouching, and prone and/or lateral
position.

**Short- and Long-Term Toxicity**
The repeat-dose oral toxicity of aripiprazole in rats was evaluated in a 13-week study (2, 6, or 20 mg/kg/day), a
52-week study (1, 3, or 10 mg/kg/day), a 4-week study (60 or 100 mg/kg/day), and a 26-week (6 month) study
(10, 30, or 60 mg/kg/day). The repeat-oral dose toxicity of aripiprazole in monkeys was evaluated in a 13-
week study (0.5, 1, 5, or 25 mg/kg/day), a 52-week study (0.5, 5, or 25 mg/kg/day), and a 39-week study (25,
50, or 75 mg/kg/day).

Aripiprazole did not cause life-threatening toxicity when given to rats at doses up to 60 mg/kg/day for 6
months or to monkeys at doses up to 75 mg/kg/day for 9 months.
CNS-related clinical signs in rats were postdose hypoactivity and ptosis and predose hyperactivity at 30 and 60 mg/kg/day in the 26-week study. Morphological changes reflective of exaggerated pharmacology or considered secondary to drug-related increases (females) or decreases (males) in serum prolactin levels were observed microscopically in the pituitary, ovaries, female reproductive tract, mammary gland, epididymides, and/or testes. These changes included atrophy of the pars intermedia of the pituitary gland, mammary gland hyperplasia (females) or atrophy (males), vaginal mucification, persistent ovarian corpora lutea, uterine atrophy, minimal to moderate testicular atrophy, and increased numbers of exfoliated germinal epithelial cells in epididymides. Drug-related direct target organ changes were limited to dose-related increased incidence and/or severity of alveolar macrophages (pulmonary histiocytosis) in lungs at all doses after 4 and 26 weeks, and minimally increased lipofuscin pigment accumulation in the adrenal cortex at 30 and 60 mg/kg/day and in the ovaries at 60 mg/kg/day after 26 weeks. In addition, an increased incidence of inflammation of the prostatic ampullary gland was seen at 30 and 60 mg/kg/day after 26 weeks. All pituitary, reproductive organ and mammary gland changes were reversible. The pulmonary histiocytosis was partially reversible. In the 52-week toxicity study in rats, which was conducted at lower doses than given in the 26-week toxicity study, NOAEL for effects was established at 1 (female) or 3 mg/kg/day (male).

In monkeys, the principal pharmacologically-mediated CNS signs (e.g., impaired motor activity, hyporeactivity, tremors, catalepsy, and abnormal posture) were most prominent during the first 1 to 2 weeks of dosing, were generally mild and transient at 5 mg/kg/day, and decreased in incidence and severity with continued dosing at 25 mg/kg/day. Similar CNS-related clinical signs were noted in the 39-week toxicity study primarily during the first 4 weeks at 25 mg/kg/day and throughout the dosing period at 50 and 75 mg/kg/day. No life-threatening clinical signs were observed at doses up to 75 mg/kg/day/day for 39 weeks or 25 mg/kg/day for 52 weeks. Gallsand (muddy substance, granular material) in bile was noted at 25 mg/kg/day after 13 weeks, and dose-related incidence of gallsand or gallstones (calculi) were observed in gallbladder at ≥25 mg/kg/day in the 39- and 52-week studies. Gallsand at 25 and 125 mg/kg/day and a gallstone at 125 mg/kg/day were also seen in the 4-week toxicity study. Minimal focal hepatolithiasis was observed at in the subscapular parenchyma (proximal to gallbladder) of liver in 2 monkeys given 50 mg/kg/day and in 1 monkey given 75 mg/kg/day for 39 weeks. There were no correlative alterations in liver functions tests. The gallsand and gallstones were considered a consequence of concentration and precipitation of sulfate conjugates, which, due to their limited solubility, precipitate out in the bile, or hydroxy metabolites of aripiprazole in the terminal biliary tree and gallbladder. No other target organs of toxicity were identified in monkeys. There was no evidence of other target organ toxicity at any dose level. In the 13-week toxicity study, drug-related changes at 25 mg/kg/day were reversible or improved during the 4-week postdose period. In the 52-week toxicity study in monkeys, which was conducted at lower doses than given in the 39-week toxicity study, the NOAEL for effects was established at 0.5 mg/kg/day.

Mutagenesis
The mutagenic potential of aripiprazole was tested in the in vitro bacterial reverse-mutation assay, the in vitro bacterial DNA repair assay, the in vitro forward gene mutation assay in mouse lymphoma cells, the in vitro chromosomal aberration assay in Chinese hamster lung (CHL) cells, the in vivo micronucleus assay in mice, and the unscheduled DNA synthesis assay in rats. Aripiprazole was clastogenic in the in vitro chromosomal aberration assay in CHL cells with and without metabolic activation. A positive response was obtained in the in vivo micronucleus assay in mice; however, the response was due to a mechanism considered not relevant to humans.22

Reproductive Toxicity
In animal studies, aripiprazole demonstrated developmental toxicity, including possible teratogenic effects in rats and rabbits. Pregnant rats were treated with oral doses of 3, 10, and 30 mg/kg/day (1, 3, and 10 times the maximum recommended human dose [MRHD] on a mg/m2 basis) of aripiprazole during the period of organogenesis. Gestation was slightly prolonged at 30 mg/kg. Treatment caused a slight delay in fetal development, as evidenced by decreased fetal weight (30 mg/kg), undescended testes (30 mg/kg), and delayed
skeletal ossification (10 and 30 mg/kg). There were no adverse effects on embryofetal or pup survival. Delivered offspring had decreased bodyweights (10 and 30 mg/kg), and increased incidences of hepatodiaphragmatic nodules and diaphragmatic hernia at 30 mg/kg (the other dose groups were not examined for these findings). A low incidence of diaphragmatic hernia was also seen in the fetuses exposed to 30 mg/kg. Postnatally, delayed vaginal opening was seen at 10 and 30 mg/kg and impaired reproductive performance (decreased fertility rate, corpora lutea, implants, and live fetuses and increased post implantation loss, likely mediated through effects on female offspring) was seen at 30 mg/kg. Some maternal toxicity was seen at 30 mg/kg; however, there was no evidence to suggest that these developmental effects were secondary to maternal toxicity.

In pregnant rats receiving aripiprazole injection intravenously (3, 9, and 27 mg/kg/day) during the period of organogenesis, decreased fetal weight and delayed skeletal ossification were seen at the highest dose, which also caused maternal toxicity. Pregnant rabbits were treated with oral doses of 10, 30, and 100 mg/kg/day (2, 3, and 11 times human exposure at MRHD based on AUC) of aripiprazole during the period of organogenesis. Decreased maternal food consumption and increased abortions were seen at 100 mg/kg. Treatment caused increased fetal mortality (100 mg/kg), decreased fetal weight (30 and 100 mg/kg), increased incidence of a skeletal abnormality (fused sternebrae at 30 and 100 mg/kg), and minor skeletal variations (100 mg/kg).

In pregnant rabbits receiving aripiprazole injection intravenously (3, 10, and 30 mg/kg/day) during the period of organogenesis, the highest dose, which caused pronounced maternal toxicity, resulted in decreased fetal weight, increased fetal abnormalities (primarily skeletal), and decreased fetal skeletal ossification. The fetal no-effect dose was 10 mg/kg, which produced 5 times the human exposure at the MRHD based on AUC. In a study in which rats were treated with oral doses of 3, 10, and 30 mg/kg/day (1, 3, and 10 times the MRHD on a mg/m² basis) of aripiprazole perinatally and postnatally (from day 17 of gestation through day 21 postpartum), slight maternal toxicity and slightly prolonged gestation were seen at 30 mg/kg. An increase in stillbirths and decreases in pup weight (persisting into adulthood) and survival were seen at this dose.

In rats receiving aripiprazole injection intravenously (3, 8, and 20 mg/kg/day) from day 6 of gestation through day 20 postpartum, an increase in stillbirths was seen at 8 and 20 mg/kg, and decreases in early postnatal pup weights and survival were seen at 20 mg/kg. These doses produced some maternal toxicity. There were no effects on postnatal behavioral and reproductive development.

**Impairment of fertility**

Female rats were treated with oral doses of 2, 6, and 20 mg/kg/day (0.6, 2, and 6 times the MRHD on a mg/m² basis) of aripiprazole from 2 weeks prior to mating through day 7 of gestation. Estrus cycle irregularities and increased corpora lutea were seen at all doses, but no impairment of fertility was seen. Increased pre-implantation loss was seen at 6 and 20 mg/kg and decreased fetal weight was seen at 20 mg/kg.

Male rats were treated with oral doses of 20, 40, and 60 mg/kg/day (6, 13, and 19 times the MRHD on a mg/m² basis) of aripiprazole from 9 weeks prior to mating through mating. Disturbances in spermatogenesis were seen at 60 mg/kg and prostate atrophy was seen at 40 and 60 mg/kg, but no impairment of fertility was seen.

**Carcinogenicity**

Lifetime carcinogenicity studies were conducted in ICR mice and in Sprague-Dawley (SD) and F344 rats. Aripiprazole was administered for 2 years in the diet at doses of 1, 3, 10, and 30 mg/kg/day to ICR mice and 1, 3, and 10 mg/kg/day to F344 rats (0.2 to 5 and 0.3 to 3 times the MRHD based on mg/m², respectively). In addition, SD rats were dosed orally for 2 years at10, 20, 40, and 60 mg/kg/day (3 to 19 times the MRHD based on mg/m²). Aripiprazole did not induce tumors in male mice or rats. In female mice, the incidences of pituitary gland adenomas and mammary gland adenocarcinomas and adenoacanthomas were increased at dietary doses of 3 to 30 mg/kg/day (0.1 to 0.9 times human exposure at MRHD based on AUC and 0.5 to 5 times the MRHD based on mg/m²). In female rats, the incidence of mammary gland fibroadenomas was increased at a dietary dose of 10 mg/kg/day (0.1 times human exposure at MRHD based on AUC); and the incidences of
adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas were increased at an oral dose of 60 mg/kg/day (10 times human exposure at MRHD based on AUC).

Proliferative changes in the pituitary and mammary gland of rodents have been observed following chronic administration of other antipsychotic agents and are considered prolactin mediated. Serum prolactin was not measured in the aripiprazole carcinogenicity studies. However, increases in serum prolactin levels were observed in female mice in a 13-week dietary study at the doses associated with mammary gland and pituitary tumors. Serum prolactin was not increased in female rats in 4- and 13-week dietary studies at the dose associated with mammary gland tumors. The relevance for human risk of the findings of prolactin-mediated endocrine tumors in rodents is unknown.

Other Toxicity Studies

Adrenocortical Changes in Rats
A series of investigative studies were conducted in rats to determine the mechanism for the aripiprazole-related adrenocortical changes after sub-chronic and chronic dosing. The data from these studies supported the conclusion that the female rat-specific adrenocortical tumorigenic response at 60 mg/kg/day in the oral carcinogenicity study was secondary to aripiprazole-related adrenocortical cytotoxicity and consequent increased cell proliferation. The female specificity of the adrenocortical tumorigenic response was considered a consequence of the earlier onset and greater severity of the adrenocortical cytotoxic changes. The adrenocortical cytotoxic and tumorigenic effects have no established clinical relevance since they occurred at a dose 10 times human exposure at the MRHD based on AUC.

Retinal Degeneration in Rats
Aripiprazole produced retinal degeneration in albino Sprague-Dawley (SD) rats in a 26-week chronic toxicity study at a dose of 60 mg/kg and in a 2-year carcinogenicity study at doses of 40 and 60 mg/kg. The 40 and 60 mg/kg doses are 7 to 10 times human exposure at the MRHD based on AUC. In a subsequent 18-month investigative study in albino SD and pigmented Long-Evans (LE) rats administered 60 mg/kg/day aripiprazole, pharmacologically mediated hyperactivity occurred in both rat strains early in the study predisposing the animals to increased light exposure. Time-dependent retinal degeneration with electroretinographic and morphologic features consistent with spontaneous light-induced retinal degeneration was observed in albino SD rats, whereas there was no evidence of light-induced retinal injury in pigmented LE rats at any timepoint despite comparable systemic exposures to aripiprazole. This was due to the photoprotective effect of ocular melanin pigment in LE rats. Therefore, the retinal degeneration observed in albino SD rats after chronic dosing at high doses of aripiprazole was considered to be a consequence of drug-related, pharmacologically mediated hyperactivity during the animal room light phase, resulting in increased light exposure rather than a direct drug effect on the retina. Light-induced retinal degeneration in albino SD rats has no established clinical relevance.
REFERENCES


PART III: CONSUMER INFORMATION

Pr ABILIFY MAINTENA®
Aripiprazole for prolonged release injectable suspension

Read this carefully before you start taking ABILIFY MAINTENA and each time you get a refill. This leaflet is a summary and will not tell you everything about ABILIFY MAINTENA. Talk to your doctor, nurse, or pharmacist about your medical condition and treatment and ask if there is any new information about ABILIFY MAINTENA.

ABOUT THIS MEDICATION

What the medication is used for:
ABILIFY MAINTENA is used for the treatment of schizophrenia in adults. Schizophrenia is characterized by symptoms such as:

- hallucinations; hearing, seeing or sensing things that are not there,
- suspiciousness, mistaken beliefs,
- incoherent speech and behavior and emotional flatness.

People with this condition may also feel depressed, guilty, anxious or tense.

ABILIFY MAINTENA is also used to treat adults who suffer from bipolar I disorder. Bipolar disorder is a condition with symptoms such as:

- feeling invincible or an all powerful inflated self-esteem,
- racing thoughts, easily losing train of thought,
- overreaction to what is seen or heard,
- misinterpretation of events,
- sped-up activity, talking very quickly, too loudly, or more than usual,
- decreased need for sleep,
- poor judgment,
- sometimes exhibiting severe irritability.

What it does:
ABILIFY MAINTENA belongs to a group of medicines called atypical antipsychotic drugs. Antipsychotic medications affect the chemicals that allow communication between nerve cells (neurotransmitters). Illnesses that affect the brain may be due to certain chemicals in the brain being out of balance. These imbalances may cause some of the symptoms you may be experiencing. Doctors and scientists are not sure what causes these imbalances to occur. Exactly how ABILIFY MAINTENA works is unknown. However, it seems to adjust the balance of chemicals called dopamine and serotonin.

You and your doctor have decided on ABILIFY MAINTENA to help relieve the symptoms that are bothering you or the patient you are caring for. Although ABILIFY MAINTENA cannot cure the illness, it can improve the symptoms and keep them under control, reducing the risk of relapse as you or the patient you’re caring for continue(s) treatment.

When it should not be used:
Do not use ABILIFY MAINTENA if you or the patient you are caring for:

- are allergic to aripiprazole or any of the ingredients listed in the “What the non-medicinal ingredients are” section of the leaflet.

What the medicinal ingredient is:
Aripiprazole

What the non-medicinal ingredients are:
Carboxymethyl cellulose sodium, mannitol, sodium phosphate monobasic monohydrate and sodium hydroxide.

What dosage forms it comes in:
300mg and 400mg vial
300mg and 400 mg Dual Chamber Syringe

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions
Various medicines of the group to which ABILIFY MAINTENA belongs have been associated with an increased rate of death when used in elderly patients with dementia. ABILIFY MAINTENA is not indicated in elderly patients with dementia.

BEFORE you or the patient you are caring for uses ABILIFY MAINTENA talk to your/their doctor, nurse or pharmacist if you/they:

- have never taken ABILIFY® (aripiprazole) tablets before.
- have diabetes or high blood sugar or a family history of diabetes or high blood sugar. Your healthcare provider should check your blood sugar before you start receiving ABILIFY MAINTENA and during your treatment.
- have or had blackouts or seizures (convulsions).
- have a history of any problems with the way your heart beats or if you are taking any medicines that may have an impact on the way your heart beats.
- suffer from high blood pressure or have rapid heart-beat and a drop in blood pressure when getting up.
- are an elderly patient suffering from dementia (loss of memory and other mental abilities), you or your care giver/relative should tell your doctor if you have ever had a stroke or "mini" stroke.
- have risk factors for developing blood clots such as: a family history of blood clots, age over 65, smoking, obesity, recent major surgery (such as hip or knee replacement), immobility due to air travel or other
• have or had low white blood cell count.
• have involuntary, irregular muscle movements, especially in the face.
• suffer from heart disease or have a family history of heart disease, stroke or "mini" stroke.
• have a condition called "congenital long QT syndrome" or "acquired long QT syndrome".
• exercise vigorously or work in hot, sunny places.
• drink alcoholic beverages or use recreational drugs.
• have ever abused drugs.
• have a history of gambling or impulse-control disorders (urge to gamble, spend money, eat or other urges).
• have a history of or are at risk of sleep apnea (a sleep disorder where your breathing is interrupted during sleep).
• have any other medical problems including problems that may affect you receiving an injection in your arm or buttocks.
• are less than 18 years old or older than 65 years of age.
• are pregnant, think you are pregnant or plan to become pregnant. It is not known if ABILIFY MAINTENA will harm your unborn baby.
• are breastfeeding or plan to breastfeed. ABILIFY MAINTENA can pass into your milk and harm your baby. Talk to your healthcare provider about the best way to feed your baby if you or the patient you are caring for receive ABILIFY MAINTENA.
• are less than 18 years old or older than 65 years of age.
• have or had low white blood cell count.
• have involuntary, irregular muscle movements, especially in the face.
• suffer from heart disease or have a family history of heart disease, stroke or "mini" stroke.
• have a condition called "congenital long QT syndrome" or "acquired long QT syndrome".
• exercise vigorously or work in hot, sunny places.
• drink alcoholic beverages or use recreational drugs.
• have ever abused drugs.
• have a history of gambling or impulse-control disorders (urge to gamble, spend money, eat or other urges).
• have a history of or are at risk of sleep apnea (a sleep disorder where your breathing is interrupted during sleep).
• have any other medical problems including problems that may affect you receiving an injection in your arm or buttocks.
• are less than 18 years old or older than 65 years of age.
• are pregnant, think you are pregnant or plan to become pregnant. It is not known if ABILIFY MAINTENA will harm your unborn baby.
• are breastfeeding or plan to breastfeed. ABILIFY MAINTENA can pass into your milk and harm your baby. Talk to your healthcare provider about the best way to feed your baby if you or the patient you are caring for receive ABILIFY MAINTENA.

Self-harm: If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straight away. You may find it helpful to tell a relative or close friend that you are depressed or have other mental illnesses, and ask them to read this leaflet. You might ask them to tell you if they think your depression or mental illness is getting worse, or if they are worried about changes in your behaviour.

Effects on newborns
In some cases, babies born to a mother taking ABILIFY MAINTENA during pregnancy have experienced symptoms that are severe and require the newborn to be hospitalized. Sometimes, the symptoms may resolve on their own. Be prepared to seek emergency medical attention for your newborn, if he/she has difficulty breathing, is overly sleepy, has muscle stiffness or floppy muscles (like a rag doll), is shaking or is having difficulty feeding.

Falls: Feeling sleepy, a fall in blood pressure when you stand up from sitting or lying down, vision and speech problems have been reported with the use of antipsychotic drugs. This can lead to falls that may cause fractures or other fall related-injuries. Certain medications, diseases or conditions can make this worse.

Driving and using machines: Because some people experience impaired judgment, thinking and motor skills, sleepiness, lightheadedness (especially when going from sitting to standing) and possible fainting, you or the patient you are caring for should avoid driving a car or operating machinery until you know how ABILIFY MAINTENA affects you/the patient you are caring for.

INTERACTIONS WITH THIS MEDICATION

Tell all doctors, dentists, nurses and pharmacists who are treating you or the patient that you are caring for that you/they are taking ABILIFY MAINTENA.

As with most medicines, interactions with other drugs are possible. Tell your doctor, nurse, or pharmacist about all the medicines you, or the patient you are caring for take, including drugs prescribed by other doctors, vitamins, minerals, natural supplements, or alternative medicines.

If you or the patient you are caring for are taking other medicines, your/their doctor may need to change the dose of ABILIFY MAINTENA.

The following may interact with ABILIFY MAINTENA:
• ketoconazole (antifungal), quinidine (antiarrhythmic), paroxetine (antidepressant), fluoxetine (antidepressant). These medicines may lead to higher concentrations of aripiprazole in your blood.
• carbamazepine. It may lead to lower concentrations of aripiprazole in your blood, making ABILIFY MAINTENA less effective.
• drugs used to lower blood pressure. ABILIFY MAINTENA may increase the effect of medicines used to lower the blood pressure.

The effects of alcohol could be made worse while taking ABILIFY MAINTENA. It is recommended that you or the patient you are caring for do not drink alcohol while taking ABILIFY MAINTENA.

Only take other medicines while you, or the patient you are caring for are on ABILIFY MAINTENA if your/their doctor tells you/them to.

PROPER USE OF THIS MEDICATION

ABILIFY MAINTENA is a long-acting medicine that a Healthcare Professional will give to you or the patient that you are caring for by injection. This means you or the patient do not have to take this medicine every day as it is designed to deliver the right amount of medication to provide sustained control for a whole month after each injection.

You or the patient you are caring for will only need to get a dose once a month.

Schizophrenia and Bipolar Disorder
Usual adult dose: The usual dose is 400 mg, once monthly, administered as a single injection in the arm or buttock by a Healthcare Professional.
IMPORTANT: PLEASE READ

You or the patient you are caring for may feel a little pain in the arm or buttock during the injection.

After the first ABILIFY MAINTENA injection, treatment should be continued with 10 mg to 20 mg oral aripiprazole (or other oral antipsychotic) for 14 days in a row to keep the right concentration of antipsychotic medicine in your/the patient you are caring for blood while switching to getting your/their medicine by injection.

Overdose:
If you think you have taken too much ABILIFY MAINTENA, contact your doctor, nurse, pharmacist, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Missed Dose:
You/the patient you are caring for should not miss a dose of ABILIFY MAINTENA. If a dose is missed for some reason, call your/their Healthcare Provider right away to let him or her know you or the patient you are caring for missed the injection and ask what you or the patient you are caring for should do next.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Side effects may include:
- insomnia
- changes in weight (gain or loss)
- feeling of restlessness
- headache
- anxiety
- the common cold
- pain at the injection site
- drowsiness
- diarrhea, nausea and vomiting
- an urge to gamble, to spend money, to eat (binge eating) or other urges (development of a new or increased urge)
- hypersexuality (uncontrollable and/or inappropriate sexual behaviour of severity or duration that causes distress)
- shaking (tremors)
- abnormal movements
- dizziness
- increased fat levels (cholesterol and triglycerides) in your blood
- hiccups
- problems with speech
- excessive sweating
- hair loss
- increased liver enzyme levels in your blood
- inflammation of the liver
- loss of consciousness and violent muscle contractions (grand mal convulsion)
- sleep apnea (a sleep disorder where your breathing is interrupted during sleep)
- sleep walking and eating while asleep (sleep-related eating disorders)

If any of these affects you severely, tell your doctor, nurse or pharmacist.

Do not drink alcohol while on ABILIFY MAINTENA treatment.

Do not become too hot or dehydrated while you receive ABILIFY MAINTENA.
- Do not exercise too much.
- In hot weather, stay inside in a cool place if possible.
- Stay out of the sun.
- Do not wear too much clothing or heavy clothing.
- Drink plenty of water.

The doctor should check body weight before starting ABILIFY MAINTENA and continue to monitor it for as long as you or the patient you are caring for are being treated.

The doctor should take blood tests before starting ABILIFY MAINTENA. These tests will monitor blood sugar, cholesterol, triglycerides and the number of infection fighting white blood cells. The doctor should continue to monitor your or the patient’s blood for as long as you or the patient you are caring for are being treated.

You should tell your doctor if you notice any symptoms that worry you or the patient you are caring for, even if you think the problems are not connected with the medicine or are not listed here.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk with your doctor, nurse or pharmacist</th>
<th>Stop taking drug and seek immediate medical help</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin Rash</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Constipation</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Uncommon</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allergic Reaction: rash, hives, swelling of the face, lips, tongue or throat, difficulty swallowing or breathing</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Symptom / effect</td>
<td>Talk with your doctor, nurse or pharmacist</td>
<td>Stop taking drug and seek immediate medical help</td>
</tr>
<tr>
<td>-----------------</td>
<td>------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td><strong>Common</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncommon</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tardive Dyskinesia: muscle twitching or unusual movement of the face or tongue</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Stroke and Transient Ischemic Attacks: Sudden weakness or numbness of the face, arms, or legs and speech or vision problems</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Seizure: Loss of consciousness with uncontrollable shaking</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Priapism: Long-lasting (greater than 4 hours in duration) and painful erection of the penis</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Blood Clots: Swelling, pain and redness in an arm or leg that is warm to touch. You may develop sudden chest pain, difficulty breathing and heart palpitations</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Decreased White Blood Cells: infections, fatigue, fever, aches, pains, and flu-like symptoms</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Dystonia: tightness of the throat, difficulty swallowing or breathing which may lead to choking</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Low Blood Pressure: dizziness, fainting, light-headedness</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>May occur when you go from lying or sitting to standing up.</td>
<td>√</td>
<td></td>
</tr>
</tbody>
</table>

This is not a complete list of side effects. For any unexpected effects while taking ABILIFY MAINTENA, contact your doctor, nurse or pharmacist.

**HOW TO STORE IT**

Dual chamber syringe:
Store between 15 and 30°C. Do not freeze. Protect the syringe from light by storing in the original package until time of use.

Vial:
ABILIFY MAINTENA should be stored between 15 and 30°C.
REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and: Fax toll-free to 1-866-678-6789, or
  Mail to: Canada Vigilance Program
  Health Canada
  Postal Locator 1908C
  Ottawa, Ontario
  K1A 0K9


NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be obtained by contacting the sponsor, Otsuka Pharmaceutical Co., Ltd., at: 1-877-341-9245.

This leaflet was prepared by Otsuka Pharmaceutical Co., Ltd.

Last revised: November 1, 2017

ABILIFY MAINTENA is a Trademark of Otsuka Pharmaceutical Co., Ltd., used under licence by Otsuka Canada Pharmaceutical Inc.